

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

REC'D 27 NOV 1936

WIPO

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office


October 17, 1996

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 08/585,895

FILING DATE: *January 12, 1996*

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



P. SWAIN

Certifying Officer

PATENT APPLICATION SERIAL NO. 585895

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FILE RECORD SHEET

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20530

PTO-1556
(5/87)

JOINT INVENTORS

"EXPRESS MAIL" mailing label No.
EG473137204US.

Date of Deposit: January 12, 1996

I hereby certify that this paper (or fee) is being
deposited with the United States Postal Service
"EXPRESS MAIL POST OFFICE TO ADDRESSEE"
service under 37 CFR §1.10 on the date
indicated above and is addressed to: Assistant
Commissioner for Patents, Washington, D.C.
20231


David A. Gass

APPLICATION FOR
UNITED STATES LETTERS PATENT

SPECIFICATION

TO ALL WHOM IT MAY CONCERN:

Be it known that we, Kari Aittalo, a citizen of Finland, residing at
Nyyrikintie 4A, 02100 Espoo, Finland, and Vladimir Joukov, a citizen of Finland,
residing at Topelluksementti 3238, 00290 Helsinki, Finland, have invented a
new and useful "RECEPTOR LIGAND", of which the following is a specification.



- 1 -

RECEPTOR LIGAND

This is a continuation-in-part of United States Patent Application
Serial Number 08/510,133, filed August 1, 1995.

FIELD OF THE INVENTION

5 The present invention generally relates to the field of genetic engineering and more particularly to growth factors for endothelial cells and growth factor genes.

BACKGROUND OF THE INVENTION

10 Developmental growth, the remodelling and regeneration of adult tissues, as well as solid tumor growth, can only occur when accompanied by blood vessel formation. Angioblasts and hematopoietic precursor cells differentiate from the mesoderm and form the blood islands of the yolk sac and the primary vascular system of the embryo. The development of blood vessels from these early (*in situ*) differentiating endothelial cells is termed
15 vasculogenesis. Major embryonic blood vessels are believed to arise via vasculogenesis, whereas the formation of the rest of the vascular tree is thought to occur as a result of vascular sprouting from pre-existing vessels, a process called angiogenesis, Risau, *et al.*, *Devel. Biol.*, 125:441-450 (1988).

 Endothelial cells give rise to several types of functionally and
20 morphologically distinct vessels. When organs differentiate and begin to perform their specific functions, the phenotypic heterogeneity of endothelial cells increases. Upon angiogenic stimulation, endothelial cells may re-enter the cell cycle, migrate, withdraw from the cell cycle and subsequently differentiate again to form new vessels that are functionally adapted to their
25 tissue environment. Endothelial cells undergoing angiogenesis degrade the underlying basement membrane and migrate, forming capillary sprouts that project into the perivascular stroma. Ausprunk, *et al.*, *Microwasc. Rev.*, 14:51-65 (1977). Angiogenesis during tissue development and regeneration depends on the tightly controlled processes of endothelial cell proliferation,
30 migration, differentiation, and survival. Dysfunction of the endothelial cell regulatory system is a key feature of many diseases. Most significantly, tumor growth and metastasis have been shown to be angiogenesis dependent. Folkman, *et al.*, *J. Biol. Chem.*, 267:10931-10934 (1992).

Key signals regulating cell growth and differentiation are mediated by polypeptide growth factors and their transmembrane receptors, many of which are tyrosine kinases. Autophosphorylated peptides within the tyrosine kinase insert and carboxyl-terminal sequences of activated receptors are commonly recognized by kinase substrates involved in signal transduction for the readjustment of gene expression in responding cells. Several families of receptor tyrosine kinases have been characterized. Van der Geer, *et al.*, *Ann. Rev. Cell Biol.*, 10:251-337 (1994). The major growth factors and receptors transducing angiogenic stimuli are schematically shown in Figure 1.

Fibroblast growth factors are also known to be involved in the regulation of angiogenesis. They have been shown to be mitogenic and chemotactic for cultured endothelial cells. Fibroblast growth factors also stimulate the production of proteases, such as collagenases and plasminogen activators, and induce tube formation by endothelial cells. Saksela, *et al.*, *Ann. Rev. Cell Biol.*, 4:93-126 (1988). There are two general classes of fibroblast growth factors, FGF-1 and FGF-2, both of which lack conventional signal peptides. Both types have an affinity for heparin and FGF-2 is bound to heparin sulfate proteoglycans in the subendothelial extracellular matrix from which it may be released after injury. Heparin potentiates the stimulation of endothelial cell proliferation by angiogenic FGFs, both by protecting against denaturation and degradation and dimerizing the FGFs. Cultured endothelial cells express the FGF-1 receptor but no significant levels of other high-affinity fibroblast growth factor receptors.

Among other ligands for receptor tyrosine kinases, the platelet derived growth factor, PDGF-BB, has been shown to be weakly angiogenic in the chick chorioallantoic membrane. Risau, *et al.*, *Growth Factors*, 7:261-266 (1992). Transforming growth factor α (TGF α) is an angiogenic factor secreted by several tumor cell types and by macrophages. Hepatocyte growth factor (HGF), the ligand of the *c-met* proto-oncogene-encoded receptor, also is strongly angiogenic.

Recent evidence shows that there are endothelial cell specific growth factors and receptors that may be primarily responsible for the stimulation of endothelial cell growth, differentiation and certain differentiated functions. The best studied of these is vascular endothelial growth factor (VEGF), a member of the PDGF family. Vascular endothelial growth factor

is a dimeric glycoprotein of disulfide-linked 23 kDa subunits. Other reported effects of VEGF include the mobilization of intracellular calcium, the induction of plasminogen activator and plasminogen activator inhibitor-1 synthesis, stimulation of hexose transport in endothelial cells, and promotion of monocyte migration *in vitro*. Four VEGF isoforms, encoded by distinct mRNA splice variants, appear to be equally capable of stimulating mitogenesis in endothelial cells. However, each isoform has a different affinity for cell surface proteoglycans, which behave as low affinity receptors for VEGF. The 121 and 165 amino acid isoforms of VEGF are secreted in a soluble form, whereas the isoforms of 189 and 206 amino acid residues remain cell surface associated and have a strong affinity for heparin.

VEGF was originally purified from several sources on the basis of its mitogenic activity toward endothelial cells, and also by its ability to induce microvascular permeability, hence it is also called vascular permeability factor (VPF). VEGF produces signals through two receptor tyrosine kinases, VEGFR-1 (FLT-1) and VEGFR-2 (KDR/Flk-1), which are expressed specifically on endothelial cells. The VEGF-related placenta growth factor (PlGF) was recently shown to bind to VEGFR-1 with high affinity. PlGF was able to enhance the growth factor activity of VEGF, but it did not stimulate endothelial cells on its own. Naturally occurring VEGF/PlGF heterodimers were nearly as potent mitogens as VEGF homodimers for endothelial cells.

The pattern of VEGF expression suggests its involvement in the development and maintenance of the normal vascular system and in tumor angiogenesis. During murine development, the entire 7.5 day post-coital (p.c.) endoderm expresses VEGF and the ventricular neuroectoderm produces VEGF at the capillary ingrowth stage. See Breier, *et al.*, *Development*, 114:521-523 (1992). On day two of quail development, the vascularized area of the yolk sac as well as the whole embryo show expression of VEGF. In addition, epithelial cells next to fenestrated endothelia in adult mice show persistent VEGF expression, suggesting a role in the maintenance of this specific endothelial phenotype and function.

Two high affinity receptors for VEGF have been characterized. These are VEGFR-1/Flt-1 (fms-like tyrosine kinase-1) and VEGFR-2/Kdr/Flk-1 (kinase insert domain containing receptor/fetal liver kinase-1). Those receptors are classified in the PDGF-receptor family, but they have seven

rather than five immunoglobulin-like loops in their extracellular domain, and they possess a longer kinase insert than normally observed in this family. The expression of VEGF receptors occurs mainly in vascular endothelial cells, although some may be present on monocytes and melanoma cells. Only
5 endothelial cells have been reported to proliferate in response to VEGF, and endothelial cells from different sources show different responses. Thus, the signals mediated through VEGFR-1 and VEGFR-2 appear to be cell type specific.

The Flt4 receptor tyrosine kinase (VEGFR-3) is closely related
10 in structure to the products of the VEGFR-1 and VEGFR-2 genes. Despite this similarity, the mature form of Flt4 differs from the VEGF receptors in that it is proteolytically cleaved in the extracellular domain into two disulfide-linked polypeptides. Pajusola *et al.*, *Cancer Res.*, 52:5738-5743 (1992). The 4.5 and 5.8 kb Flt-4 mRNAs encode polypeptides which differ in their C-
15 termini due to the use of alternative 3' exons. The VEGFs do not show specific binding to Flt4 or induce its autophosphorylation.

Expression of Flt4 appears to be more restricted than expression of VEGFR-1 or VEGFR-2. The expression of Flt4 first becomes detectable by
20 *in situ* hybridization in the angioblasts of head mesenchyme, the cardinal vein, and extraembryonically in the allantois of 8.5 day p.c. mouse embryos. In 12.5 day p.c. embryos the Flt-4 signal is observed in developing venous and presumptive lymphatic endothelia, but arterial endothelia appear negative. During later stages of development, Flt4 mRNA becomes restricted to
25 developing lymphatic vessels. Only the lymphatic endothelia and some high endothelial venules express Flt4 mRNA in adult human tissues and increased expression occurs in lymphatic sinuses in metastatic lymph nodes and in lymphangioma. These results support the theory of the venous origin of lymphatic vessels.

Five endothelial cell specific receptor tyrosine kinases, Flt-1
30 (VEGFR-1), KDR/Flk-1 (VEGFR-2), Flt4, Tie and Tek/Tie-2 have so far been described, which possess the intrinsic tyrosine kinase activity essential for signal transduction. Targeted mutations inactivating Flt-1, Flk-1, Tie and Tek in mouse embryos have indicated their essential and specific roles in vasculogenesis and angiogenesis at the molecular level. VEGFR-1 and
35 VEGFR-2 bind VEGF with high affinity (K_d 16 pM and 760 pM, respectively)

and VEGFR-1 also binds the related placenta growth factor (PlGF; K_d about 200 pM), while the ligands for Tie, Tek, and Flt4 have not yet been reported.

SUMMARY OF THE INVENTION

The present invention provides a ligand for the Flt4 receptor tyrosine kinase. Thus, the invention provides a purified and isolated polypeptide which specifically binds to the Flt4 receptor tyrosine kinase. In a preferred embodiment, the ligand comprises a fragment of the amino acid sequence shown in SEQ ID NO: 33 which specifically binds to the Flt4 receptor tyrosine kinase.

The present invention also provides a precursor of an Flt4 ligand, wherein the precursor comprises the amino acid sequence shown in SEQ ID NO: 33. Thus, the invention includes a purified and isolated polypeptide having the amino acid sequence shown in SEQ ID NO: 33.

A putative 32 amino acid signal peptide has been identified in the amino acid sequence shown in SEQ ID NO: 33. Thus, in a related aspect, the invention includes a purified and isolated polypeptide comprising amino acids 1-318 of SEQ ID NO: 33. The Flt4 ligand precursor is proteolytically cleaved upon expression to produce an approximately 23 kD peptide which is the Flt4 ligand (herein designated VEGF-C). Thus, the invention includes a polypeptide having an amino acid sequence comprising a portion of SEQ ID NO: 2, the portion encoding a fragment capable of specifically binding to Flt4. A preferred fragment has a molecular weight of about 23 kDa as assessed by SDS-PAGE under reducing conditions. In a preferred embodiment of the invention, an Flt4 ligand is provided which is the cleavage product of the precursor peptide shown in SEQ ID NO: 33 and which has a molecular weight of approximately 23 kD under reducing conditions.

Evidence suggests that the amino acids essential for retaining Flt4 ligand activity are contained within approximately amino acids 1-120 of SEQ ID NO: 33, and that the proteolytic cleavage to produce a mature, naturally-occurring Flt4 ligand occurs within approximately amino acids 1-180 of SEQ ID NO: 33. Accordingly, preferred polypeptide of the invention include polypeptides comprising amino acids 1-120, 1-121, 1-122, 1-123, 1-124 ... 1-178, 1-179, and 1-180 of SEQ ID NO: 33, wherein said polypeptides specifically bind to an Flt4 receptor tyrosine kinase. A preferred Flt4 ligand

comprises approximately amino acids 1-120 of SEQ ID NO: 33. Another preferred polypeptide of the invention comprises approximately amino acids 1-180 of SEQ ID NO: 33.

5 The present invention also provides a cDNA encoding a novel polypeptide, designated VEGF-C, that is structurally homologous to VEGF. VEGF-C is a ligand for the FLT4 receptor tyrosine kinase (VEGFR-3), a receptor tyrosine kinase related to VEGFR-1 and VEGFR-2 that does not bind VEGF. VEGFR-3 is expressed in venous and lymphatic endothelia of fetal
10 tissues and predominantly in lymphatic endothelial of adult tissues. Kaipainen et al., *Cancer Res.*, 54:6571-77 (1994); Kaipainen et al., *Proc. Natl. Acad. Sci. USA*, 92:3566-70 (1995).

Thus, in a preferred embodiment, the invention includes a purified and isolated nucleic acid (e.g., a DNA or an RNA) encoding an Flt4
15 ligand precursor. Due to the degeneracy of the genetic code, numerous such coding sequences are possible, each having in common the coding of the amino acid sequence shown in SEQ ID NO: 33. As set forth above, the invention includes polypeptides which comprise a portion of the amino acid sequence shown in SEQ ID NO: 33 and which bind the Flt4 receptor tyrosine
20 kinase (herein designated VEGFR-3); the invention also is intended to include nucleic acids encoding these polypeptides. Ligand precursors according to the invention, when expressed in an appropriate host cell, produce, via cleavage, a peptide which binds specifically to the Flt4 receptor tyrosine kinase (VEGFR-3). The nucleotide sequence shown in SEQ ID NO:32 contains a preferred
25 nucleotide sequence encoding the Flt4 ligand (VEGF-C).

25 The present invention also provides a cell line which produces an Flt4 ligand. The ligand may be purified and isolated directly from the cell culture medium. Also provided are vectors comprising a DNA encoding the Flt4 ligand, and host cells comprising the vectors. Preferred vectors of the invention are capable of expressing the Flt4 ligand under the control of
30 appropriate promoters and other control sequences. A preferred vector of the invention is plasmid pFLT4-L, having ATCC accession no. 97521.

The invention further includes a method of making polypeptides of the invention. In a preferred method, a nucleic acid or vector of the invention is expressed in a host cell, and a polypeptide of the invention is
35 purified from the host cell or the host cell growth medium.

In another aspect, the invention includes an antibody which is specifically reactive with polypeptides of the invention. Antibodies, both monoclonal and polyclonal, may be made against a ligand of the invention according to standard techniques in the art. Such antibodies may be used in diagnostic applications to monitor angiogenesis, vascularization, lymphatic vessels and their disease states, wound healing, or certain hematopoietic or leukemia cells, or they may be used to block or activate the Flt4 receptor.

Ligands according to the invention may be labeled with a detectable label and used to identify their corresponding receptors *in situ*. Labeled Flt4 ligand and anti-Flt4 ligand antibodies may be used as imaging agents in the detection of lymphatic vessels, high endothelial venules, and Flt4 receptors expressed in histochemical tissue sections. The ligand or antibody may be covalently or non-covalently coupled to a suitable supermagnetic, paramagnetic, electron dense, echogenic, or radioactive agent for imaging. Other, non-radioactive labels, such as biotin and avidin, may also be used.

The present invention also provides diagnostic and clinical applications for claimed ligands. In a preferred embodiment, Flt4 ligands or precursors are used to accelerate angiogenesis, *e.g.*, during wound healing, or to promote the endothelial functions of lymphatic vessels. Ligands may be applied in any suitable manner using an appropriate pharmaceutically-acceptable vehicle. Ligands also may be used to quantify future metastatic risk by assaying biopsy material for the presence of active receptors or ligands in a binding assay or kit using detectably-labeled ligand. An Flt4 ligand according to the invention also may be used to promote re-growth or permeability of lymphatic vessels in, for example, organ transplant patients. Ligands according to the invention also may be used to treat or prevent inflammation, edema, aplasia of the lymphatic vessels, lymphatic obstruction, elephantiasis, and Milroy's disease. Finally, Flt4 ligands may be used to stimulate lymphocyte production and maturation, and to promote or inhibit trafficking of leukocytes between tissues and lymphatic vessels or to affect migration in and out of the thymus.

Inhibitors of the Flt4 ligand may be used to control endothelial cell proliferation and lymphangiomas. For example, such inhibitors may be used to arrest metastatic growth or spread, or to control other aspects of endothelial cell expression and growth. Inhibitors include antibodies, antisense

oligonucleotides, and peptides which block the Flt4 receptor, all of which are intended as aspects of the invention.

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 is a schematic diagram showing major endothelial cell
5 receptor tyrosine kinases and growth factors involved in vasculogenesis and angiogenesis.

Figure 2 schematically depicts the construction of the pLTRFlt4l expression vector.

Figure 3 schematically depicts the construction of the
10 baculovirus vector encoding a secreted soluble Flt4 extracellular domain (Flt4EC).

Figure 4 shows results of stimulation of Flt4 autophosphorylation by conditioned medium from PC-3 cell cultures.

Figure 5 shows that the major tyrosyl phosphorylated
15 polypeptide of Flt4-transfected cells stimulated with PC-3 conditioned medium is the 125 kD Flt4 polypeptide (VEGFR-3).

Figure 6 shows Western analysis of the Flt4 ligand activity isolated from PC-3 conditioned medium.

Figure 7 shows results of gel electrophoresis of fractions from
20 the Western analysis of Flt4 ligand (VEGF-C) isolated from PC-3 conditioned medium.

Figure 8 shows results of Western analysis of Flt4 autophosphorylation induced by either the Flt4 ligand (VEGF-C), VEGF, or PIGF.

Figure 9A schematically depicts the cloning and analysis of the
25 Flt4 ligand, VEGF-C. The VEGF-C coding sequence (shaded boxes) and signal sequence (ss) are depicted between 5' and 3' untranslated (ut) nucleic acid regions.

Figure 9B shows the nucleotide and deduced amino acid
30 sequence of the coding portion of Flt4 ligand cDNA. The cleavage site for the putative signal peptide is indicated with a shaded triangle.

Figure 10 shows a comparison of the deduced amino acid sequences of PDGF-A, -B, two PIGF isoforms, four VEGF isoforms and Flt4 ligand (VEGF-C).

Figure 11 shows the stimulation of autophosphorylation of the Flt4 receptor by conditioned medium from cells transfected with the Flt4-L (VEGF-C) expression vector.

Figure 12 shows Northern blotting analysis of Flt4-L (VEGF-C) mRNA in tumor cell lines.

Figure 13A is an autoradiograph showing recombinant VEGF-C isolated following a pulse-chase experiment and electrophoresed via SDS-PAGE under reducing conditions.

Figure 13B is a photograph of polyacrylamide gel showing that recombinant VEGF-C forms are disulfide-linked in nonreducing conditions.

Figure 14A and 14B depict Western blots showing that VEGF-C stimulates autophosphorylation of VEGFR-2 (KDR) but has no effect on PDGFR- β phosphorylation.

Figure 15A and 15B show that VEGF-C stimulates endothelial cell migration in a three-dimensional collagen gel assay.

Figure 16A shows the expression of VEGF-C mRNA in human adult tissues.

Figure 16B shows the expression of VEGF, VEGF-B, and VEGF-C in selected human fetal tissues.

Figure 17 schematically depicts the chromosomal localization of the VEGF-C gene.

Figure 18 is a Northern blot hybridization study showing the effects of hypoxia on the mRNA expression of VEGF-A, VEGF-B and VEGF-C.

DETAILED DESCRIPTION OF THE INVENTION

Described herein is the isolation of a novel vascular endothelial growth factor and its cloning from a cDNA library prepared from the human prostatic adenocarcinoma cell line PC-3. The isolated cDNA encodes a protein which is proteolytically processed and secreted to cell culture medium.

The secreted protein, designated VEGF-C, binds to the extracellular domain of Flt4 (designated VEGFR-3) and induces tyrosine autophosphorylation of Flt4 and VEGFR-2. VEGF-C also stimulates the migration of endothelial cells in collagen gel.

The present invention also is directed to novel growth factors

which are ligands for the Flt4 receptor tyrosine kinase (VEGFR-3). Claimed ligands are members of a family of platelet-derived growth factors/vascular endothelial growth factors which promote mitosis and proliferation of vascular endothelial cells and/or mesodermal cells. Ligands recognizing the Flt4 receptor tyrosine kinase were purified from a PC-3 prostatic adenocarcinoma cell line (ATCC CRL1435). When applied to a population of cells expressing the Flt4 receptor, ligands of the invention stimulate autophosphorylation, resulting in receptor activation. The invention also provides inhibitors of the Flt4 receptor, including antibodies directed against the ligand. A ligand according to the invention may be coexpressed as a larger precursor which is cleaved to produce the ligand. A coexpressed region in some cases results from alternative splicing of RNA of the ligand gene. Such a co-expressed region may be a function of the particular expression system used to obtain the ligand. The skilled artisan understands that in recombinant production of proteins, additional sequence may be expressed along with a functional peptide depending upon the particular recombinant construct used to express the protein, and subsequently removed to obtain the desired ligand. In some cases the recombinant ligand can be made lacking certain residues of the endogenous/natural ligand. Moreover, it is well-known in that conservative replacements may be made in a protein which do not alter the function of the protein. Accordingly, it is anticipated that such alterations are within the scope of the claims. It is intended that the precursor sequence shown in SEQ ID NO: 33 is capable of stimulating the Flt4 ligand without any further processing in a manner similar to that in which VEGF stimulates its receptor in its unprocessed form.

Results reported herein show that VEGFR-3 transmits signals for a novel growth factor. This conclusion is based on the specific binding of VEGF-C to recombinant Flt4EC (Flt4 extracellular domain) protein and the induction of VEGFR-3 autophosphorylation by medium from VEGF-C transfected cells. In contrast, VEGF and PlGF did not show specific binding to VEGFR-3 to induce its autophosphorylation.

A major part of the difference in the observed molecular mass of the purified and recombinant VEGF-C and the deduced molecular mass of the VEGF-C encoded by the VEGF-C open reading frame (ORF) may be due to proteolytic removal of sequences in the carboxyl terminal region of the

latter. Proteolytic processing of the VEGF-C precursor may occur at more than one cleavage site because the 32 kD molecular mass of the recombinant secreted ligand was also less than the deduced molecular mass of VEGF-C ORF without the signal peptide. By extrapolation from studies of the structure of PDGF (Heldin, *et al.*, *Growth Factors*, 8:245-52 (1993)), one can speculate that the region critical for receptor binding and activation by VEGF-C is contained within the amino-terminal first 180 or so amino acid residues the secreted of VEGF-C protein lacking the signal sequence. In fact, the region critical for receptor binding and activation by VEGF-C is believed to be contained within the first approximately 120 amino acid residues of the secreted VEGF-C protein lacking the signal sequence. Thus, the 23 kD polypeptide binding VEGFR-3 is likely to represent the VEGF-homologous domain. After biosynthesis, the nascent VEGF-C polypeptide may be glycosylated at three putative N-linked glycosylation sites identified in the deduced VEGF-C amino acid sequence.

The carboxyl terminal amino acid sequences, which increase the length of the VEGF-C polypeptide in comparison with other ligands of this family, show a pattern of spacing of cysteine residues reminiscent of the Balbaini ring 3 protein (BR3P) sequence (Dignam and Case, *Gene*, 88:133-40 (1990); Paulsson, *et al.*, *J. Mol. Biol.*, 211:331-49 (1990)). This novel C-terminal silk protein-like structural motif of VEGF-C may fold into an independent domain, which, on the basis of the considerations above, is at least partially cleaved off after biosynthesis. Interestingly, at least one cysteine motif of the BR3P type is also found in the carboxyl terminus of VEGF. In our experiments both the putative precursor and cleaved ligand were detected in the cell culture media, although processing was apparently cell-associated on the basis of the pulse-chase experiments. The determination of the amino terminal sequence of the isolated carboxyl terminal fragment will allow the identification of the proteolytic processing site. The generation of antibodies against different parts of the VEGF-C molecule will allow the exact determination of the precursor-product relationship and ratio, their cellular distribution, and the kinetics of processing and secretion.

VEGF-C has a conserved pattern of eight cysteine residues, which may participate in the formation of intra- and interchain disulfide bonds, creating an antiparallel dimeric biologically active molecule, similar to PDGF.

Mutational analysis of the cysteine residues involved in the interchain disulfide bridges have shown that, in contrast to PDGF, VEGF dimers need to be held together by these covalent interactions in order to maintain biological activity. Disulfide linking of the VEGF-C polypeptide chain was evident in the analysis of VEGF-C in nonreducing conditions.

VEGFR-3, which thus distinguishes between VEGF and VEGF-C, is closely related to structure to VEGFR-1 and VEGFR-2. Finnerty, *et al.*, *Oncogene*, 8:2293-98 (1993); Galland, *et al.*, *Oncogene*, 8:1233-40 (1993); Pajusola, *et al.*, *Cancer Res.*, 52:5738-43 (1992). However, the mature form of VEGFR-3 differs from the two other VEGFRs in that it is proteolytically cleaved in the extracellular domain into two disulfide-linked polypeptides. Pajusola, *et al.*, *Oncogene*, 9:3545-55 (1994). Another difference is that the 4.5 and 5.8 kb VEGFR-3 mRNAs encode polypeptides differing in their C-termini and apparently in their signalling properties due to the use of alternative 3' exons. Borg *et al.*, *Oncogene*, 10:973-84 (1995); Pajusola *et al.*, *Oncogene*, 8:2931-37 (1993).

Besides VEGFR-3, VEGFR-2 tyrosine kinase also is activated in response to VEGF-C. VEGFR-2 mediated signals cause striking changes in the morphology, actin reorganization and membrane ruffling of porcine aortic endothelial cells overexpressing this receptor. In these cells, VEGFR-2 also mediated ligand-induced chemotaxis and mitogenicity. Waltenberger *et al.*, *J. Biol. Chem.*, 269:26988-95 (1994). Similarly, the receptor chimera CSF-1R/VEGFR-3 was mitogenic when ectopically expressed in NIH3T3 fibroblastic cells, but not in porcine aortic endothelial cells (Pajusola *et al.*, 1994). Consistent with such results, the bovine capillary endothelial cells, which express VEGFR-2 mRNA but very little or no VEGFR-1 or VEGFR-3 mRNAs, showed enhanced migration when stimulated with VEGF-C. As shown here, light microscopy of the BCE cell cultures in collagen gel also suggested that VEGF-C stimulated the proliferation of these cells. The already existing data thus indicate that the VEGF ligands and receptors show a great specificity in their signalling, which may be cell type dependent.

The expression pattern of the VEGFR-3 (Kaipainen *et al.*, *Proc. Natl. Acad. Sci. USA*, 92:3566-70 (1995)) suggests that VEGF-C may function in the formation of the venous and lymphatic vascular systems during embryogenesis. Constitutive expression of VEGF-C in adult tissues shown

herein further suggests that this gene product also is involved in the maintenance of the differentiated functions of the lymphatic endothelium where VEGFR-3 is expressed (Kaipainen et al., 1995). Lymphatic capillaries do not have well formed basal laminae and an interesting possibility remains that the silk-like BR3P motif is involved in producing a supramolecular structure which could regulate the availability of VEGF-C in tissues. However, as shown here, VEGF-C also activates VEGFR-2, which is abundant in proliferating endothelial cells of vascular sprouts and branching vessels of embryonic tissues, but decreased in adult tissues. Millauer et al., *Nature*, 367:576-78 (1993). These data have suggested that VEGFR-2 is a major regulator of vasculogenesis and angiogenesis. VEGF-C may thus have a unique effect in lymphatic endothelium and a more redundant function shared with VEGF in angiogenesis and possibly permeability regulation of several types of endothelia. Because VEGF-C stimulates the VEGFR-2 and promotes endothelial migration, a utility for VEGF-C is suggested as an inducer of angiogenesis of blood and lymphatic vessels in wound healing, tissue transplantation, in eye diseases, in the formation of collateral vessels to around arterial stenoses and into injured tissues after infarction.

Taken together, these results show an increased complexity of signalling in the vascular endothelium. They reinforce the concept that when organs differentiate and begin to perform their specific functions, the phenotypic heterogeneity of endothelial cells increases in several types of functionally and morphologically distinct vessels. However, upon suitable angiogenic stimuli, endothelial cells can re-enter the cell cycle, migrate, withdraw from the cell cycle and subsequently differentiate again to form new vessels that are functionally adapted to their tissue environment. This process of angiogenesis concurrent with tissue development and regeneration depends on the tightly controlled balance between positive and negative signals for endothelial cell proliferation, migration, differentiation and survival. Previously-identified growth factors promoting angiogenesis include the fibroblast growth factors, hepatocyte growth factor/scatter factor, PDGF and TGF- α . (See, e.g., Folkman, *Nature Med.* 1:27-31 (1995); Friesel and Maciag, *FASEB J.* 9:919-25 (1995); Mustonen and Alitalo, *J. Cell Biol.*, 129:895-98 (1995). However, VEGF has been the only growth factor relatively specific for endothelial cells. The newly identified factors VEGF-B

and VEGF-C thus increase our understanding of the complexity of the specific and redundant positive signals for endothelial cells involved in vasculogenesis, angiogenesis, permeability and perhaps also other endothelial functions.

Also described herein is the localization of the VEGF-C genes
5 in human chromosomes by analysis of somatic cell hybrids and fluorescence *in situ* hybridization (FISH). Southern blotting and polymerase chain reaction analysis of somatic cell hybrids and fluorescence *in situ* hybridization of metaphase chromosomes was used to assess the chromosomal localization of the VEGF-C gene. The VEGF-C gene was located on chromosome 4q34,
10 close to the human aspartylglucosaminidase gene previously mapped to 4q34-35. The VEGF-C locus in 4q34 is a candidate target for mutations leading to vascular malformations or cardiovascular diseases. Expression studies by Northern blotting and hybridization show abundant VEGF-C
15 expression in heart and skeletal muscle; other tissues, such as lung and kidney, also express these genes. Whereas PlGF is predominantly expressed in the placenta, the expression patterns of the three VEGFs overlap in many tissues, which suggests that they may form heterodimers and interact to exert their physiological functions.

Targeted mutagenesis leading to inactivation of the VEGF
20 receptor loci in the mouse genome have shown that VEGFR-1 is necessary for the proper organization of endothelial cells forming the vascular endothelium, while VEGFR-2 is necessary for the generation of both endothelial and hematopoietic cells. This suggests that the four genes of the VEGF family can be targets for mutations leading to vascular malformations or cardiovascular
25 diseases.

The following Examples illustrate preferred embodiments of the invention, wherein the isolation, characterization, and function of Flt4 ligands and ligand-encoding nucleic acids according to the invention are shown.

EXAMPLE 1

30 Production of pLTR-Flt4l expression vector

Construction of the LTR-Flt4l vector is schematically shown in Figure 2. The full-length Flt4s cDNA (Genbank Accession No. X68203) was assembled by first subcloning the S2.5 fragment, reported in Pajusola *et al.*, *Cancer Res.* 52:5738-5743 (1992), incorporated by reference herein,

containing base pairs 56-2534 of the Flt4s into the *EcoRI* site of the pSP73 vector (Promega, Madison, WI).

Since cDNA libraries used for screening of Flt4 cDNAs did not contain its most 5' protein-coding sequences, inverse PCR was used for the
5 amplification of the 5' end of Flt4 corresponding to the first 12 amino acid residues (MQRGAALCLRLW). Poly(A)⁺ RNA was isolated from the HEL cells and double-stranded cDNA copy was synthesized using the Amersham cDNA Synthesis System Plus kit and a gene specific primer: 5'-TGTCCTCGCTGTCCTTGCT-3' (SEQ ID NO: 1), which was located 195
10 bp downstream of the 5' end of clone S2.5. Double stranded cDNA was treated with T4 DNA polymerase to blunt the ends and cDNA was purified with Centricon 100 (Amicon Inc., Beverly, MA). Circularization was made in a total volume of 150 ul. The reaction mixture contained ligation buffer, 5% PEG-8000, 1 mM DTT and 8U of T4 DNA ligase (New England Biolabs).
15 Ligation was carried out at 16°C for 16 hours. Fifteen µl of this reaction mix was used in a standard 100 ul PCR reaction containing 100 ng of specific primers including *SacI* and *PstI* restriction sites, present in this segment of the Flt4 cDNA, and 1 unit of Taq DNA polymerase (Perkin Elmer Cetus). Two rounds of PCR were performed using 33 cycles (denaturation at 95°C for 1
20 minute, annealing at 55°C for 2 minutes and elongation at 72°C for 4 minutes). The PCR mixture was treated sequentially with the *SacI* and *PstI* restriction enzymes and after purification with MagicPCR Preps (Promega) DNA fragments were subcloned into the pGEM3Zf(+) vector for sequencing. The sequence obtained corresponds to the 5' end of the Flt4s cDNA clone
25 deposited in the Genbank Database as Accession No. X68203.

The sequence encoding the first 12 amino acid residues was added to the expression construct by ligating an *SphI* digested PCR fragment amplified using reverse transcription-PCR of poly(A)⁺ RNA isolated from the HEL cells using the oligonucleotides 5'-ACATGCATGC CACCATGCAG
30 CGGGGCGCCG CGCTGTGCCT GCGACTGTGG CTCTGCCTGG GACTCCTGGA-3' (SEQ ID NO: 2)(forward primer, *SphI* site underlined, the translational start codon marked in bold follows an optimized Kozak consensus sequence Kozak, *Nucl. Acids Res.* 15: 8125-8148, 1987) and 5'-ACATGCATGC CCCGCCGGT CATCC-3' (SEQ ID NO: 3) (reverse primer,
35 *SphI* site underlined) to the 5' end of the S2.5 fragment, thus replacing unique

SphI fragment of the S2.5 plasmid. The resulting vector was digested with *EcoRI* and *Clal* and ligated to a 138 bp PCR fragment amplified from the 0.6 kb *EcoRI* fragment (base pairs 3789 to 4416 in the Genbank X68203 sequence) which encodes the 3' end of Flt4s shown in Figure 1 of Pajusola *et al.*, *Cancer Res.* 52:5738-5743, 1992, using the oligonucleotides 5'-
5 CGGAATTC CATGACCCCA AC-3' (SEQ ID NO: 4) (forward, *EcoRI* site underlined) and 5'-CCATCGATGG ATCTACCTG AAGCCGCTTT CTT-3' (SEQ ID NO: 5) (reverse, *Clal* site underlined). The coding domain was completed by ligation of the 1.2 kb *EcoRI* fragment (base pairs 2535-3789
10 of sequence X68203) into the above construct. The complete cDNA was subcloned as a *HindIII-Clal*(blunted) fragment (this *Clal* site was also included in the 3' primer used to construct the 3' end of the coding sequence) to the pLTRpoly expression vector reported in Mäkelä *et al.*, *Gene*, 118: 293-294 (1992) (Genbank accession number X60280), incorporated by reference herein,
15 using its *HindIII-Acc I*(blunted) restriction sites.

The long form of Flt4 was produced by replacing the 3'-end of the short form as follows: The 3' region of the Flt4l cDNA was PCR-amplified using a gene specific and a pGEM 3Z vector specific (SP6 promoter) oligonucleotide 5'-ATTTAGGTGACACTATA-3' (SEQ ID NO: 6) as reverse
20 and forward primers, respectively, and an Flt4l cDNA clone containing a 495 bp *EcoRI* fragment extending downstream of the *EcoRI* site at nucleotide 3789 of the Genbank X68203 sequence (the sequence downstream of this *EcoRI* site is deposited as the Flt4 long form 3' sequence having Genbank accession number S66407). The gene specific oligonucleotide contained a *BamHI*
25 restriction site located right after the end of the coding region. The sequence of that (reverse primer) oligonucleotide was 5'-CCATCGATGGATCCCGATGCTGCTTAGTAGCTGT-3' (SEQ ID NO: 7) (*BamHI* site is underlined). The PCR product was digested with *EcoRI* and *BamHI* and transferred in frame to LTRFlt4s vector fragment from which the
30 coding sequences downstream of the *EcoRI* site at base pair 2535 (see sequence X68203) had been removed by *EcoRI-BamHI* digestion. Again, the coding domain was completed by ligation of the 1.2 kb *EcoRI* fragment (base pairs 2535-3789 of sequence X68203) back into the resulting construct.

EXAMPLE 2

Production and analysis of Flt4 transfected cells

NIH3T3 cells (60 % confluent) were co-transfected with 5 μ g of the pLTRFlt4l construct and 0.25 μ g of the pSV2neo vector (ATCC) containing the neomycin phosphotransferase gene, using the DOTAP liposome-based transfection reagents (Boehringer Mannheim, Mannheim, Germany). One day after the transfection the cells were transferred into selection media containing 0.5 mg/ml geneticin (GIBCO, Grand Island, N.Y.). Colonies of geneticin-resistant cells were isolated and analysed for expression of the Flt4 proteins. Cells were lysed in boiling lysis buffer containing 3.3% SDS (sodium dodecyl sulphate), 125 mM Tris, pH 6.8. Protein concentrations of the samples were measured by the BCA method (Pierce, Rockford, IL). About 50 μ g protein of each lysate was analysed for the presence of Flt4 by 6% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting using antisera against the carboxyl terminus of Flt4 and the ECL method (Amersham).

For production of anti-Flt4 antiserum the Flt4 cDNA fragment encoding the 40 carboxyterminal amino acid residues of the short form: NH₂-PMIPTTYKG SVDNQTDSGM VLASEEFEQI ESRHRQESGFR-COOH (SEQ ID NO: 8) was cloned as a 657 bp *EcoRI*-fragment into the pGEX-1 λ T bacterial expression vector (Pharmacia) in frame with the glutathione-S-transferase coding region. The resultant GST-Flt4S fusion protein was produced in *E.coli* and purified by affinity chromatography using a glutathione-Sepharose 4B column. The purified protein was lyophilized, dissolved in phosphate buffered saline (PBS), mixed with Freund's adjuvant and used for immunization of rabbits at biweekly intervals using methods standard in the art (Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988). Antisera were used after the fourth booster immunization for immunoprecipitation of Flt4 from the transfected cells and cell clones expressing Flt4 were used for ligand stimulation analysis.

EXAMPLE 3

Construction of a Flt4 EC baculovirus vector and expression and purification of its product

The construction of an Flt4 extracellular domain (EC)

5 baculovirus vector is schematically shown in Figure 3. The Flt4-encoding
cDNA has been prepared in both a long form and a short-form, each being
incorporated in a vector under control of the Moloney murine leukemia virus
LTR promoter. The nucleotide sequence of the short form of the Flt4 receptor
is available on the Genbank database as Accession No. X68203 and the
10 specific 3' segment of the long form cDNA is available as Accession No.
S66407.

The ends of a cDNA segment encoding Flt4 extracellular
domain (EC) were modified as follows: The 3' end of Flt4 cDNA sequence
(Genbank Accession Number X68203) which encodes the extracellular domain
15 was amplified using primer 1116 5'-CTGGAGTCGACTTGGCGGACT-3'
(SEQ ID NO: 9, *Sall* site underlined) and primer 1315 5'-
CGCGGATCCCTAGTGATGGTGATGGTGATGTCTACCTTCGATCATGCT
GCCCTTAT CCTC-3' (SEQ ID NO: 10, *Bam*HI site underlined). The
sequence complementary to that of primer 1315 continues after the Flt4
20 reading frame and encodes 6 histidine residues for binding to a Ni-NTA
column (Qiagen, Hilden, Germany) followed by a stop codon, and an added
Bam HI site. The amplified fragment was digested with *Sall* and *Bam*HI and
used to replace a unique *Sall*-*Bam*HI fragment in the LTRFlt4 vector shown in
Figure 3. The *Sall*-*Bam*HI fragment that was replaced encodes the Flt4
25 transmembrane and cytoplasmic domains.

The 5' end without the Flt4 signal sequence encoding region
was amplified by PCR using the primer 1335 5'-
CCCAAGCTTGGATCCAAGTGGCTACTCCATGACC-3' (SEQ ID NO: 11)
(the primer contains added *Hind*III (AAGCTT) and *Bam*HI (GGATCC)
30 restriction sites, which are underlined) and primer 1332 5'-
GTTGCCTGTGATGTGCACCA-3' (SEQ ID NO: 12). The amplified
fragment was digested with *Hind*III and *Sph*I (the *Hind*III site (AAGCTT) is
underlined in primer 1335 and the *Sph*I site is within the amplified region of
the Flt4 cDNA). The resultant *Hind*III-*Sph*I fragment was used to replace a
35 *Hind*III-*Sph*I fragment in the modified LTRFlt4 vector described immediately

above (the *HindIII* site is in the 5' junction of the Flt4 insert with the pLTRpoly portion of the vector, the *SphI* site is in Flt4 cDNA). The resultant Flt4EC insert was then ligated as a *BamHI* fragment into the *BamHI* site in the pVTBac plasmid as disclosed in Tessier *et al.*, *Gene* 98: 177-183 (1991),
5 incorporated by reference herein. The orientation was confirmed to be correct by partial sequencing so that the open reading frame of the signal sequence-encoding portion of the vector continued in frame with the Flt4 sequence. That construct was transfected together with the baculovirus genomic DNA into SF-9 cells by lipofection. Recombinant virus was purified, amplified and
10 used for infection of High-Five cells (Invitrogen, San Diego, CA) using methods standard in the art. The Flt4 extracellular domain (Flt4EC) was purified from the culture medium of the infected High-Five cells using Ni-NTA affinity chromatography according to manufacturer's instructions (Qiagen) for binding and elution of the 6xHis tag encoded in the COOH-
15 terminus of the recombinant Flt4 extracellular domain.

EXAMPLE 4

Isolation of Flt4 Ligand from Conditioned Media

An Flt4 ligand according to the invention was isolated from conditioned media from PC-3 prostatic adenocarcinoma cell line CRL1435
20 from the American Type Culture Collection and cultured as instructed by the supplier in Ham's F-12 Nutrient mixture (GIBCO) containing 7% fetal calf serum. In order to prepare the conditioned media, confluent PC-3 cells were cultured for 7 days in Ham's F-12 Nutrient mixture (GIBCO) in the absence of fetal bovine serum. Medium was then cleared by centrifugation at 10,000 g
25 for 20 minutes. The medium was then screened to determine its ability to induce tyrosine phosphorylation of Flt4 by exposure to NIH3T3 cells which had been transfected with Flt4-encoding cDNA using the pLTRFlt41 vector. For receptor stimulation experiments, subconfluent NIH3T3 cells were starved overnight in serum-free DMEM medium (GIBCO) containing 0.2% BSA. The
30 cells were stimulated with the conditioned media for 5 minutes, washed twice with cold PBS containing 100 μ M vanadate and lysed in RIPA buffer (10 mM Tris pH 7.5, 50 mM NaCl, 0.5% sodium deoxycholate, 0.5% Nonidet P40 (BDH, Poole, England), 0.1% SDS, 0.1 U/ml Aprotinin (Boehringer Mannheim), 1 mM vanadate) for receptor immunoprecipitation analysis. The

lysates were centrifuged for 20 minutes at 15,000 x g. The supernatants were incubated for 2 hours on ice with 3 ul of the antiserum against the Flt4 C-terminus described in Example 2 and also in Pajusola, *et al.* *Oncogene* 8: 2931-2937, (1993), incorporated by reference herein.

5 After a 2 hour incubation in the presence of anti-Flt4 antiserum, protein A-Sepharose (Pharmacia) was added and incubation was continued for 45 minutes with rotation. The immunoprecipitates were washed three times with the immunoprecipitation buffer and twice with 10 mM Tris, pH7.5 before
10 analysis in SDS-PAGE. Polypeptides were transferred to nitrocellulose and analyzed by Western blotting using Flt4- or phosphotyrosine-specific antisera and the ECL method (Amersham International, Buckinghamshire, England). Anti-phosphotyrosine monoclonal antibodies (anti-PTyr, PY20) were purchased from Transduction Laboratories (Lexington, Kentucky). In some cases, the filters were restained with a second antibody after stripping. The stripping of
15 the filters was done for 30 minutes at 50°C in 100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl pH 6.7 with occasional agitation.

As shown in Figure 4, the PC-3 cell conditioned medium stimulated tyrosine phosphorylation of a 125 kD polypeptide when Flt4-expressing NIH3T3 cells were treated with the indicated preparations of
20 media, lysed, and the lysates were immunoprecipitated with anti-Flt4 antiserum followed by SDS-PAGE, Western blotting, and staining using anti-PTyr antibodies. The resulting band was weakly phosphorylated upon stimulation with unconcentrated PC-3 conditioned medium (lane 2). The 125 kD band comigrated with the tyrosine phosphorylated, processed form of the
25 mature Flt4 from pervanadate-treated cells (compare lanes 2 and 7 of Fig. 4, see also Figure 5A). Comigration was confirmed upon restaining with anti-Flt4 antibodies as is also shown in Figure 5A (panel on the right). In order to show that the 125 kD polypeptide is not a non-specific component of the conditioned medium reactive with anti-phosphotyrosine antibodies, 15 ul of
30 conditioned medium was separated by SDS-PAGE, blotted on nitrocellulose and the blot was stained with anti-PTyr antibodies. No signal was obtained (Fig. 5B). Also, unconditioned medium failed to stimulate Flt4 phosphorylation, as shown in Figure 4, lane 1.

As shown in Figure 4, lane 3, stimulating activity was
35 considerably increased when the PC-3 conditioned medium was concentrated

four-fold using a Centricon-10 concentrator (Amicon). Figure 4, lane 4, shows that pretreatment of the concentrated PC-3 conditioned medium with 50 μ l of the Flt4 extracellular domain coupled to CNBr-activated sepharose CL-4B (Pharmacia; about 1mg of Flt4EC domain/ml sepharose resin) completely abolished Flt4 tyrosine phosphorylation. Similar pretreatment of the conditioned medium with unsubstituted sepharose CL-4B did not affect stimulatory activity, as shown in Figure 4, lane 5. Also, the flow through obtained after concentration, which contained proteins of less than 10,000 molecular weight, did not stimulate Flt4 phosphorylation, as shown in Figure 4, lane 6.

The foregoing data show that PC-3 cells produce a ligand which binds to the extracellular domain of Flt4 and activates this receptor.

EXAMPLE 5

Purification of the Flt4 Ligand

The ligand expressed by PC-3 cells as characterized in Example 3 was purified and isolated using a recombinantly-produced Flt4 extracellular domain (Flt4EC) in affinity chromatography.

Two harvests of serum-free conditioned medium, comprising a total of 8 L, were collected from 500 confluent 15 cm diameter culture dishes containing confluent layers of PC-3 cells. The conditioned medium was clarified by centrifugation at 10,000 x g and concentrated 80-fold using an Ultrasette Tangential Flow Device (Filtron, Northborough, MA) with a 10 kD cutoff Omega Ultrafiltration membrane according to the manufacturer's instructions. Recombinant Flt4 extracellular domain was expressed in a recombinant baculovirus cell system and purified by affinity chromatography on Ni-agarose (Ni-NTA affinity column obtained from Qiagen). The purified extracellular domain was coupled to CNBr-activated Sepharose CL-4B at a concentration of 5 mg/ml and used as an affinity matrix for ligand affinity chromatography.

Concentrated conditioned medium was incubated with 2 ml of the recombinant Flt4 extracellular domain-Sepharose affinity matrix in a rolling tube at room temperature for 3 hours. All subsequent purification steps were at +4 °C. The affinity matrix was then transferred to a column (Pharmacia) with an inner diameter of 15 mm and washed successively with

100 ml of PBS and 50 ml of 10 mM Na-phosphate buffer (pH 6.8). Bound material was eluted step-wise with 100 mM glycine-HCl, successive 6 ml elutions having pHs of 4.0, 2.4, and 1.9. Several 2 ml fractions of the eluate were collected in tubes containing 0.5 ml 1 M Na-phosphate (pH 8.0).

5 Fractions were mixed immediately and dialysed in 1 mM Tris-HCl (pH 7.5). Aliquots of 75 μ l each were analyzed for their ability to stimulate tyrosine phosphorylation of Flt4. The ultrafiltrate, 100 μ l aliquots of the concentrated conditioned medium before and after ligand affinity chromatography, as well as 15-fold concentrated fractions of material released from the Flt4
10 extracellular domain-Sepharose matrix during the washings were also analyzed for their ability to stimulate Flt4 tyrosine phosphorylation.

As shown in Figure 6, lane 3, the concentrated conditioned medium induced prominent tyrosine phosphorylation of Flt4 in transfected NIH3T3 cells overexpressing Flt4. This activity was not observed in
15 conditioned medium taken after medium was exposed to the Flt4 Sepharose affinity matrix described above (lane 4). The specifically-bound Flt4-stimulating material was retained on the affinity matrix upon washes in PBS, 10 mM Na-phosphate buffer (pH 6.8), and at pH 4.0 (lanes 5-7, respectively), and it was eluted in the first two 2 ml aliquots at pH 2.4 (lanes 8 and 9). A
20 further decrease of the pH of the elution buffer did not cause release of additional Flt4-stimulating material (lane 11).

Small aliquots of the chromatographic fractions were concentrated in a SpeedVac concentrator (Savant, Farmingdale, N.Y.) and subjected to SDS-PAGE under reducing conditions with subsequent silver
25 staining of the gel. As shown in Figure 7, the major polypeptide, having a molecular weight of approximately 23 kD (reducing conditions), was detected in the fractions containing Flt4 stimulating activity (corresponding to lanes 8 and 9 in Figure 6). That polypeptide was not found in the other chromatographic fractions. On the other hand, all other components detected
30 in the two active fractions were also distributed in the starting material and in small amounts in the other washing and elution steps after their concentration. Similar results were obtained in three independent affinity purifications, indicating that the 23 kD polypeptide specifically binds to Flt4 and induces its tyrosine phosphorylation.

Fractions containing the 23 kD polypeptide were combined, dried in a SpeedVac concentrator and subjected to SDS-PAGE in a 12.5 % gel. The proteins from the gel were then electroblotted to Immobilon-P (PVDF) transfer membrane (Millipore, Malborough, MA) and visualized by staining of the blot with Coomassie blue R-250. The region containing only the stained 23 kD band was cut from the blot and was subjected to N-terminal amino acid sequence analysis in a Prosite Protein Sequencing System (Applied Biosystems, Foster City, CA). The data were analyzed using a 610A Data Analysis System (Applied Biosystems). Analysis revealed a single N-terminal sequence of NH₂-XEETIKFAAAHYNTEILK-COOH (SEQ ID NO: 13).

EXAMPLE 6

Construction of PC-3 cell cDNA library in a eukaryotic expression vector.

Poly(A)⁺ RNA was isolated from five 15 cm diameter confluent dishes of PC-3 cells by a single step method using oligo(dT) (Type III, Collaborative Research) cellulose affinity chromatography (Sambrook et al., Molecular Cloning, A Laboratory Manual; Cold Spring Harbor Laboratory Press, 1989). The yield was 70 µg. Six micrograms of the Poly(A)⁺ RNA was used to prepare an oligo(dT)-primed cDNA library in the mammalian expression vector pcDNA I and the Librarian kit of Invitrogen according to the instructions included in the kit. The library was estimated to contain about 10⁶ independent recombinants with an average insert size of approximately 1.8 kb.

EXAMPLE 7

Amplification of the unique nucleotide sequence encoding the Flt4 ligand

Degenerate oligonucleotides were designed based on the N-terminal amino acid sequence of the isolated Flt4 ligand and were used as primers in a polymerase chain reaction (PCR) to amplify cDNA encoding the Flt4 ligand from a PC-3 cell library. The overall strategy is schematically depicted in Fig. 9A, where the different primers have been marked with arrows.

The PCR was carried out using 1 µg of DNA from the amplified PC-3 cDNA library and a mixture of sense-strand primers

comprising 5'-GCAGARGARACNATHAA-3' (SEQ ID NO: 14)(wherein R is A or G, N is A,G,C or T and H is A, C or T), encoding amino acid residues 2-6 (EETIK, SEQ ID NO: 15) and antisense-strand primers 5'-GCAYTTNARDATYTCNGT-3' (SEQ ID NO: 16) (wherein Y is C or T and D is A, G or T), corresponding to amino acid residues 14-18 (TEILK, SEQ ID NO: 17). Three extra nucleotides (GCA) were added to the 5'-terminus of each primer to increase annealing stability. Two successive PCR runs were carried out using 1 U per reaction of DynaZyme (F-500L, Finnzymes), a thermostable DNA polymerase, in a buffer supplied by the manufacturer (10 mM Tris-HCl, pH 8.8 at 25 °C, 1.5 mM MgCl₂, 50 mM KCl, 0.1% Triton-X100), at an extension temperature of 72 °C. The first PCR run was carried out for 43 cycles. The first three cycles were run at an annealing temperature of 33 °C for 2 minutes, and the remaining cycles were run at 42 °C for 1 minute.

The region of the gel containing a weak band of the expected size (57 bp) was cut out from the gel and eluted. The eluted material was reamplified for 30 cycles using the same primer pairs described above at 42°C for 1 minute. The amplified fragment was cloned into a pCR II vector (Invitrogen) using the TA cloning kit (Invitrogen) and sequenced using the radioactive dideoxynucleotide sequencing method of Sanger. Six clones were analysed and all contained the sequence encoding the expected peptide (amino acids 2-18 of the Flt4 ligand precursor). Nucleotide sequence spanning the region from the third nucleotide of codon 6 to the third nucleotide of codon 13 (the extension region) was identical in all six clones: 5'-ATTCGCTGCAGCACACTACAAC-3' (SEQ ID NO: 18) and thus was considered to represent an amplified product from the unique sequence encoding part of the amino terminus of the Flt4 ligand.

EXAMPLE 8

Amplification of the 5'-end of the cDNA encoding the Flt4 ligand

Based on the unique nucleotide sequence encoding the N-terminus of the isolated Flt4 ligand, two pairs of nested primers were designed to amplify, in two subsequent PCR-reactions, the complete 5'-end of the corresponding cDNAs from one microgram of DNA from the above-described

PC-3 cDNA library. First, amplification was performed with primer 5'-TCNGTGTTGTAGTGTGCTG-3' (SEQ ID NO: 19), which is the antisense-strand primer corresponding to amino acid residues 9-15 (AAHYNTE, SEQ ID NO: 20), and sense-strand primer 5'-TAATACGACTCACTATAGGG-3' (SEQ ID NO: 21), corresponding to the T7 RNA promoter of the pcDNA1 vector used for construction of the library. "Touchdown" PCR was used as disclosed in Don, *et al.*, *Nucl. Acids Res.*, 19: 4008 (1991), incorporated by reference herein. The annealing temperature of the two first cycles was 62 °C and subsequently the annealing temperature was decreased in every other cycle by 1 °C until a final temperature of 53 °C was reached, at which temperature 16 additional cycles were conducted. Annealing time was 1 minute and extension at each cycle was conducted at 72 °C for 1 minute. Multiple amplified DNA fragments were obtained in the first reaction. The products of the first amplification (1 ul of a 1:100 dilution in water) were used in the second amplification reaction employing the nested primers 5'-GTTGTAGTGTGCTGCAGCGAATTT-3' (SEQ ID NO: 22), an antisense-strand primer corresponding to amino acid residues 6-13 (KFAAAHYN, SEQ ID NO: 23) of the Flt4 ligand, and 5'-TCACTATAGGGAGACCCAAGC-3' (SEQ ID NO: 24), a sense-strand primer corresponding to nucleotides 2179-2199 of the pcDNA1 vector. The sequences of these sense and antisense primers overlapped with the 3' ends of the corresponding primers used in the first PCR. "Touchdown" PCR was carried out by decreasing the annealing temperature from 72 °C to 66 °C and continuing with 18 additional cycles at 66 °C. The annealing time was 1 minute and extension at each cycle was carried out at 72 °C for 2 minutes. One major product of about 220 bp and three minor products of about 270 bp, 150 bp, and 100 bp were obtained.

The amplified fragment of approximately 220 bp was cut out from the agarose gel, cloned into a pCRII vector using the TA cloning kit (Invitrogen) and sequenced. Three recombinant clones were analysed and they contained the sequence 5'-

TCACTATAGGGAGACCCAAGCTTGGTACCGAGCTCGGATCCACTAGT
AACGGCCGCCAGTGTGGTGGAAATTCGACGAACTCATGACTGTACTCT
ACCCCAGAATATTGGAAAAATGTACAAGTGTTCAGCTAAGGCAAGGAGGC
TGGCAACATAACAGAGAACAGGCCAACCTCAACTCAAGGACAGAAG
AGACTATAAAATTCGCTGCAGCAGACTACAAC- 3' (SEQ ID NO: 25).

The beginning of the sequence represents the pcDNA1 vector and the underlined sequence represents the amplified product of the 5'-end of the insert. The ATG codon located upstream of that sequence in the same reading frame is followed by an open reading frame containing the amplified product of the putative signal sequence and the first 13 amino acid residues of the secreted Flt4 ligand. The cloning of the 5' end of the Flt4 cDNA, as described in the preceding two examples, is depicted schematically in Fig. 9A.

EXAMPLE 9

Amplification of the 3'-end of cDNA encoding the Flt4 ligand

Based upon the amplified 5'-sequence of the clones encoding the Flt4 ligand, two pairs of non-overlapping nested primers were designed to amplify the 3'-portion of the FLT4-L clones. The sense-strand primer 5'-ACAGAGAACAGGCCAACC-3' (SEQ ID NO: 26) and antisense-strand primer 5'-TCTAGCATTTAGGTGACAC-3' (SEQ ID NO: 27) corresponding to nucleotides 2311-2329 of the pcDNA1 vector were used in a first "touchdown" PCR. The annealing temperature of the reaction was decreased 1°C every two cycles from 72°C to 52°C, at which temperature 15 additional cycles were carried out. The annealing time was 1 minute and extension at each cycle was carried out at 72°C for 3 minutes. DNA fragments of several sizes were obtained in the first amplification. Those products were diluted 1:200 in water and reamplified in PCR using the second pair of primers: 5'-AAGAGACTATAAAATTCGCTGCAGC-3' (SEQ ID NO: 28) and 5'-CCCTCTAGATGCATGCTCGA-3' (SEQ ID NO: 29) (antisense-strand primer corresponding to nucleotides 2279-2298 of the pcDNA1 vector). Two DNA fragments were obtained, having sizes of 1350 bp and 570 bp. Those fragments were cloned into a pCRII vector and the inserts of the clones were sequenced. Both of these fragments were found to contain sequences encoding an amino acid sequence homologous to the VEGF sequence.

EXAMPLE 10

Screening the PC-3 cell cDNA library using the 5' PCR fragment of Flt4 ligand cDNA

A 219 bp 5'-terminal fragment of Flt4 ligand cDNA was amplified by PCR using the 5' PCR fragment described above and primers 5'-GTTGTAGTGTGCTGCAGCGAATTT-3' (antisense-strand primer, SEQ ID

NO: 30) and 5'-TCACTATAGGGAGACCCAAGC-3' (SEQ ID NO: 31)
(sense-primer corresponding to nucleotides 2179-2199 of the pcDNA1 vector).

The amplified product was subjected to digestion with *EcoRI* (Boehringer Mannheim) to remove the portion of the DNA sequence amplified from the
5 pcDNA1 vector and the resulting 153 bp fragment encoding the 5' end of the Flt4 ligand was labeled with [³²P]-dCTP using the Klenow fragment of *E. coli* DNA polymerase I (Boehringer Mannheim). That fragment was used as a probe for hybridization screening of the amplified PC-3 cell cDNA library.

Filter replicas of the library were hybridized with the
10 radioactively labeled probe at 42 °C for 20 hours in a solution containing 50% formamide, 5x SSPE, 5x Denhardt's solution, 0.1% SDS and 0.1 mg/ml denatured salmon sperm DNA. Filters were washed twice in 1x SSC, 0.1% SDS for 30 minutes at room temperature, then twice for 30 minutes at 65 °C and exposed overnight.

15 On the basis of autoradiography, 10 positive recombinant bacterial colonies hybridizing with the probe were chosen from the library. Plasmid DNA was purified from these colonies and analysed by *EcoRI* and *NotI* digestion and agarose gel electrophoresis followed by ethidium bromide staining. The ten plasmid clones were divided into three groups on the basis
20 of the presence of insert sizes of approximately 1.7, 1.9 and 2.1 kb, respectively. Inserts of plasmids from each group were sequenced using the T7 oligonucleotide as a primer and walking primers for subsequent sequencing reactions.

Sequence analysis showed that all clones contain the open
25 reading frame encoding the NH2-terminal sequence of the Flt4 ligand. Furthermore, the 2.1 and 1.9 kb clones also contained sequences encoding the signal sequence (Fig. 9A, SS). The 5' end of the 1.7 kb clone began within the signal sequence-encoding portion. Dideoxy sequencing was continued using walking primers in the downstream direction. An 1140 nucleotide
30 portion of the sequence of the longest clone is shown in Figure 9B. As can be seen in that figure, after the putative signal sequence the open reading frame terminates in a TAA stop codon 318 amino acid residues further downstream from the 32 amino acid signal sequence. When compared with sequences in the GenBank Database, the predicted protein product of this reading frame was
35 found to be homologous with the predicted amino acid sequences of the

PDGF/VEGF family of growth factors, as shown in Figure 10.

EXAMPLE 11

Stimulation of Flt4 autophosphorylation by the protein product of the Flt4 ligand vector

5 The 2.1 kb insert of the Flt4-L clone in pcDNA1 vector containing the open reading frame encoding the sequence shown in Fig. 9B (SEQ ID NO: 32) was cut out from the vector using *HindIII* and *NotI* restriction enzymes, isolated from a preparative agarose gel and ligated to the corresponding sites in the pREP7 expression vector (Invitrogen). The pREP7
10 vector containing the above cloned insert was transfected into 293-EBNA cells (Invitrogen) using the calcium phosphate transfection method (Sanbrook et al., Molecular Cloning, A Laboratory Manual; Cold Spring Harbor Laboratory Press, 1989). About 48 hours after transfection the medium of the transfected cells was changed to DMEM medium lacking fetal calf serum and incubated
15 for 36 h. The thus conditioned medium was then collected, centrifuged at 5000 x g for 20 minutes, the supernatant was concentrated 5-fold using Centrprep 10 (Amicon) and used to stimulate NIH3T3 cells expressing LTRFlt4l, as in Example 4. The cells were lysed, immunoprecipitated using anti-Flt4 antiserum and analysed by Western blotting using anti-
20 phosphotyrosine antibodies.

As can be seen from Fig. 11, lanes 1 and 3, the conditioned medium from two different dishes of the transfected cells stimulated Flt4 autophosphorylation in comparison with the medium from mock-transfected cells, which gave only background levels of phosphorylation of the Flt4
25 receptor (lane 2). When the concentrated conditioned medium was pre-absorbed with 20 μ l of a slur of Flt4EC domain coupled to Sepharose (see example 4), no phosphorylation was obtained (lane 4), showing that the activity responsible for Flt4 autophosphorylation was indeed the Flt4 ligand. Thus, these results demonstrate that the Flt4-L plasmid vector clone having an
30 approximately 2.1 kb insert and containing the open reading frame shown in Fig. 9B is expressed into a Flt4 ligand in cells transfected with the Flt4-L expression vector clone, and thus is biologically active. The sequence encoded by that open reading frame is shown in SEQ ID NO: 33. Plasmid pFLT4-L has been deposited with the American Type Culture Collection, 12301

Parklawn Drive, Rockville, MD 20852 as accession number 97231.

However, the predicted molecular weight of the mature protein product deduced from this reading frame is 35881 and the Flt4 ligand from PC-3 cell cultures had an approximate molecular weight of 23 kD under
5 reducing conditions. It is thus possible that the Flt4-L mRNA may be first translated into a precursor, from which the mature ligand is derived by proteolytic cleavage. The difference in the observed molecular weight of the isolated Flt4 ligand and the deduced molecular weight of the disclosed open
10 reading frame of the Flt4 ligand sequence may then derive from sequences in the carboxyl terminal region of the latter. Also, the Flt4 ligand may be glycosylated at two putative N-linked glycosylation sites conforming to the consensus which can be identified in the deduced Flt4 ligand amino acid
sequence (N-residues underlined in Fig. 10).

The carboxyl terminal amino acid sequences, which increase the
15 predicted molecular weight of the Flt4 ligand subunit in comparison with other ligands of this family, show a pattern of spacing of cysteine residues reminiscent of the Balbiani ring protein 3 (BRP3) sequence (Dignam and Case, Gene 88, 133-140, 1990), as depicted in Fig. 9A. Such a sequence may
20 encode an independently folded domain present in a Flt4 ligand precursor and it may be involved, for example, in the regulation of secretion, solubility, stability, cell surface localization or activity of the Flt4 ligand. Interestingly, at least one cysteine motif of the BRP3 type is also found in the VEGF
carboxy terminal amino acid sequences.

Thus, the Flt4-L mRNA may be first translated into a precursor
25 from the mRNA corresponding to the Flt4-L clone, from which the mature ligand is derived by proteolytic cleavage. To define the mature Flt4 ligand product one first expresses the cDNA clone, which is deposited in the pcDNA1 expression vector, in cells, such as COS cells. One uses antibodies generated
against Flt4-L-encoded peptides, such as amino terminal 23 amino acid peptide
30 or bacterial Flt4 fusion proteins, such as a GST-fusion protein, to raise antibodies against the VEGF-homologous domain of Flt4 ligand. One then follows the biosynthesis and processing of the Flt4 ligand in the transfected cells by pulse-chase analysis using radioactive cysteine for labelling of the cells, immunoprecipitation and gel electrophoresis. Using antibodies against
35 the two domains of the product of the Flt4-L clone material for radioactive or

nonradioactive aminoterminal sequence analysis is isolated. The determination of the NH₂-terminal sequence of the carboxyl terminal fragment allows for identification of the proteolytic processing site. This is confirmed by site-directed mutagenesis of the amino acid residues adjacent to the cleavage site, which would prevent the cleavage.

On the other hand, the Flt4 ligand is characterized by progressive 3' deletions in the 3' coding sequences of the Flt4 ligand precursor clone, resulting in carboxy-terminal truncations of its protein product. The activities of such truncated forms are assayed by, for example, studying Flt4 autophosphorylation induced by the truncated proteins when applied to cultures of cells, such as NIH3T3 cells expressing LTRFlt4. By extrapolation from studies of the structure of the related platelet derived growth factor (PDGF, reference Heldin *et al.*, *Growth Factors* 8:245-252 (1993)) one determines that the region critical for receptor activation by the Flt4 ligand is contained within its first approximately 180 amino acid residues of the secreted VEGF-C protein lacking the signal sequence, and apparently within the first approximately 120 amino acid residues.

On the other hand, the difference between the molecular weights of the purified ligand and the open reading frame of the Flt4 precursor clone may be due to the fact that the soluble ligand was produced from an alternatively spliced mRNA which would also be present in the PC-3 cells, from which the isolated ligand was derived. To isolate such alternative cDNA clones one uses cDNA fragments of the deposited clone and PCR primers made according to the sequence provided as well as techniques standard in the art to isolate or amplify alternative cDNAs from the PC-3 cell cDNA library. One may also amplify using reverse transcription (RT)-PCR directly from the PC-3 mRNA using the primers provided in the sequence of the Flt4-L clone. Alternative cDNA sequences are determined from the resulting cDNA clones. One can also isolate genomic clones corresponding to the Flt4-L transcript from a human genomic DNA library using methods standard in the art and to sequence such clones or their subcloned fragments to reveal the corresponding exons. Alternative exons can then be identified by a number of methods standard in the art, such as heteroduplex analysis of cDNA and genomic DNA, which are subsequently be characterized.

EXAMPLE 12

Expression of the Flt4-L gene

Expression of transcripts corresponding to the Flt4 ligand (VEGF-C) was analysed by hybridization of Northern blots containing isolated poly(A)⁺ RNA from HT-1080 and PC-3 human tumor cell lines. The probe was the radioactively labelled insert of the 2.1 kb cDNA clone (specific activity 10^8 - 10^9 cpm/mg of DNA). The blot was hybridized overnight at 42°C using 50% formamide, 5 x SSPE buffer, 2% SDS, 10 x Denhardt's solution, 100 mg/ml salmon sperm DNA and 1×10^6 cpm of the labelled probe/ml. The blot was washed at room temperature for 2 x 30 minutes in 2 x SSC containing 0.05% SDS, and then for 2 x 20 min at 52°C in 0.1 x SSC containing 0.1% SDS. The blot was then exposed at -70°C for three days using intensifying screens and Kodak XAR film. Both cell lines expressed an Flt4 ligand mRNA of about 2.3 kb, as well as VEGF and VEGF-B mRNAs (Fig. 12).

EXAMPLE 13

VEGF-C Chains Are Proteolytically Processed after Biosynthesis and Disulfide Linked

The predicted molecular mass of the secreted polypeptide, as deduced from the VEGF-C ORF, is 35,881 kD, suggesting that VEGF-C mRNA may be first translated into a precursor, from which the mature ligand of 23 kD is derived by proteolytic cleavage.

To study this, Metabolic labelling of 293 EBNA cells transfected with the VEGF-C construct was carried out by addition of 100 μ Ci/ml of Pro-mixTM L-[³⁵S] *in vitro* cell labelling mix (Amersham) to the culture medium devoid of cysteine and methionine. After two hours, the cell layers were washed twice with PBS and the medium was then replaced with DMEM-0.2% BSA. After 1, 3, 6, 12 and 24 hours of subsequent incubation, the culture medium was collected, clarified by centrifugation, and concentrated, and VEGF-C was bound to 30 ml of a slurr of Flt4EC-Sepharose overnight at +4°C, followed by three washes in PBS, two washes in 20 mM Tris-HCl (pH 7.5), alkylation, SDS-PAGE and autoradiography.

These experiments demonstrated that a putative precursor polypeptide of 32 kD apparent molecular mass was bound to the Flt4EC

affinity matrix from the CM of metabolically labelled cells transfected with a VEGF-C expression vector (Fig. 13A). Increased amounts of a 23 kD receptor binding polypeptide accumulated in the culture medium during a subsequent chase period of 3 h, but not thereafter (lanes 2-4 and data not shown), suggesting that the 23 kD form is produced by proteolytic processing, which is cell-associated and incomplete, at least in the transiently transfected cells. The arrows in Fig. 13A indicate the 32 kDa and 23 kDa polypeptides of secreted VEGF-C.

In a related experiment, VEGF-C isolated using Flt4EC-Sepharose after a 4 h continuous metabolic labelling was analyzed by polyacrylamide gel electrophoresis in nonreducing conditions (Fig. 13B). Higher molecular mass forms were observed under nonreducing conditions, suggesting that the VEGF-C polypeptides can form disulfide-linked dimers and/or multimers (arrows in Fig. 13B).

EXAMPLE 14

Stimulation Of VEGFR-2 Autophosphorylation By VEGF-C

Conditioned medium (CM) from 293 EBNA cells transfected with the VEGF-C vector also was used to stimulate porcine aortic endothelial (PAE) cells expressing VEGFR-2. Pajusola et al., *Oncogene*, 9:3545-55 (1994); Waltenberger et al., *J. Biol. Chem.*, 269:26988-95 (1994). The cells were lysed and immunoprecipitated using VEGFR-2 - specific antiserum (Waltenberger et al., 1994).

PAE-KDR cells (Waltenberger et al., 1994) were grown in Ham's F12 medium-10% fetal calf serum (FCS). Confluent NIH3T3-Flt4 cells or PAE-KDR cells were starved overnight in DMEM or Ham's F12 media, respectively, supplemented with 0.2% bovine serum albumin (BSA) and then incubated for 5 min. with the analyzed media. Recombinant human VEGF (R&D Systems) and PDGF-BB were used as a control stimulating agents. The cells were washed twice with ice-cold tris-buffered saline (TBS) containing 100 mM sodium orthovanadate and lysed in RIPA buffer containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 U/ml aprotinin and 1 mM sodium orthovanadate. The lysates were sonicated, clarified by centrifugation at 16,000 g for 20 min. and incubated for 3-6 h on ice with 3-5 ml of antisera specific for Flt4 (Pajusola et al., 1993), VEGFR-2 or PDGFR- β

(Claesson-Welsh et al., *J. Biol. Chem.*, 264:1742-47 (1989); Waltenberger et al., 1994). Immunoprecipitates were bound to protein A-Sepharose, washed three times with TBS containing 1mM PMSF, 1mM sodium orthovanadate, twice with 10 mM Tris-HCl (pH 7.4) and subjected to SDS-PAGE in a 7% gel. Polypeptides were transferred to nitrocellulose by Western blotting and analysed using PY20 phosphotyrosine-specific monoclonal antibodies (Transduction Laboratories) or receptor-specific antiserum and ECL method (Amersham).

The results of the experiment are presented in Figs. 14A and 14B. As shown in Fig. 14A, PAE cells expressing VEGFR-2 were stimulated with 10- or 2-fold concentrated medium from mock-transfected 293-EBNA cells (lanes 1 and 2), or with 2-, 5- or 10-fold concentrated medium from 293-EBNA cell cultures expressing the recombinant VEGF-C (lanes 3-6). VEGFR-2 was immunoprecipitated with specific antibodies and analysed by SDS-PAGE and Western blotting using phosphotyrosine antibodies. For comparison, the stimulations were carried out with non-conditioned medium containing 50 ng/ml of purified recombinant VEGF (lanes 7 and 8). Lanes 6 and 7 show stimulation with VEGF-C- or VEGF- containing media pretreated with Flt4EC. As depicted in Fig. 14B, PDGFR- β -expressing NIH3T3 cells were stimulated with non-conditioned medium (lane 1), 5-fold concentrated CM from mock-transfected (lane 2) or VEGF-C - transfected (lanes 3 and 4) cells, or with non-conditioned medium containing 50 ng/ml of recombinant human PDGF-BB (lane 5). Medium containing VEGF-C was also pretreated with recombinant Flt4EC (lane 4). PDGFR- β was immunoprecipitated with specific antibodies and analysed by SDS-PAGE and Western blotting using phosphotyrosine antibodies with subsequent stripping and reprobing of the membrane with antibodies specific for PDGFR- β .

A basal level of tyrosine phosphorylation of VEGFR-2 was detected in cells stimulated by CM from the mock-transfected cells. A further concentration of this medium resulted in only a slight enhancement of VEGFR-2 phosphorylation (lanes 1 and 2). CM containing recombinant VEGF-C stimulated tyrosine autophosphorylation of VEGFR-2 and the intensity of the autophosphorylated polypeptide band was increased upon concentration of the VEGF-C CM (lanes 3-5). Furthermore, the stimulating effect was abolished after pretreatment of the medium with the Flt4EC affinity matrix (compare

lanes 1, 5 and 6). The maximal effect of VEGF-C in this assay was comparable to the effect of recombinant VEGF added to unconditioned medium at concentration of 50 ng/ml (lane 8). Pretreatment of the medium containing VEGF with Flt4EC did not abolish its stimulating effect on VEGFR-2 (compare lanes 7 and 8). These results suggest that the VEGF-C expression vector encodes a ligand not only for Flt4 (VEGFR-3), but also for VEGFR-2.

In order to further confirm that the stimulating effect of VEGF-C on tyrosine phosphorylation of VEGFR-3 and VEGFR-2 was receptor-specific, we analysed the effect of VEGF-C on tyrosine phosphorylation of PDGF receptor β (PDGFR- β) which is abundantly expressed on fibroblastic cells. As can be seen from Fig. 14B, a weak tyrosine phosphorylation of PDGFR- β was detected upon stimulation of Flt4-expressing NIH3T3 cells with CM from the mock-transfected cells (compare lanes 1 and 2). A similar low level of PDGFR- β phosphorylation was observed when the cells were incubated with CM from the VEGF-C transfected cells, with or without prior treatment with Flt4EC (lanes 3 and 4). In contrast, the addition of 50 ng/ml of PDGF-BB induced a prominent tyrosine autophosphorylation of PDGFR- β (lane 5).

EXAMPLE 15

VEGF-C Stimulates Endothelial Cell Migration In Collagen Gel

CM from cell cultures transfected with the VEGF-C expression vector was placed in a well made in collagen gel and used to stimulate the migration of bovine capillary endothelial (BCE) cells in the three-dimensional collagen gel as follows.

BCE cells (Folkman et al., *Proc. Nat'l Acad. Sci. USA*, 76:5217-5221 (1979) were cultured as described in (Pertovaara et al., *J. Biol. Chem.*, 269:6271-74 (1994)). The collagen gels were prepared by mixing type I collagen stock solution (5 mg/ml in 1 mM HCl) with an equal volume of 2x *MEM* and 2 volumes of *MEM* containing 10% newborn calf serum to give a final collagen concentration of 1.25 mg/ml. The tissue culture plates (5 cm diameter) were coated with about 1 mm thick layer of the solution, which was allowed to polymerize at 37°C. BCE cells were seeded on top of this layer.

For the migration assays, the cells were allowed to attach inside a plastic ring (1 cm diameter) placed on top of the first collagen layer. After 30 min., the ring was removed and unattached cells were rinsed away. A second layer of collagen and a layer of growth medium (5% newborn calf serum (NCS)), solidified by 0.75% low melting point agar (FMC BioProducts, Rockland, ME), were added. A well (3 mm diameter) was punched through all the layers on both sides of the cell spot at a distance of 4 mm, and the sample or control media were pipetted daily into the wells. Photomicrographs of the cells migrating out from the spot edge were taken after six days through an Olympus CK 2 inverted microscope equipped with phase-contrast optics. The migrating cells were counted after nuclear staining with the fluorescent dye bisbenzimidazole (1 mg/ml, Hoechst 33258, Sigma).

Fig. 15A depicts a comparison of the number of cells migrating at different distances from the original area of attachment towards wells containing media conditioned by the non-transfected (control) or transfected (mock; VEGF-C; VEGF) cells, 6 days after addition of the media. The number of cells migrating out from the original ring of attachment was counted in five adjacent 0.5 mm x 0.5 mm squares using a microscope ocular lens grid and 10x magnification. Cells migrating further than 0.5 mm were counted in a similar way by moving the grid in 0.5 mm steps. The experiments were carried out twice with similar results, and medium values from the one of the experiments are presented with standard error bars. The photographs in Fig. 15B depict phase-contrast microscopy and fluorescent microscopy of the nuclear staining of BCE cells migrating towards the wells containing media conditioned by the mock-transfected cells or by VEGF-C - transfected cells. The areas shown is approximately 1mm x 1.5mm, and arrows indicate the borders of the original ring of attachment.

After 6 days of treatment, the cultures were stained and cells at different distances outside of the original ring of attachment were counted using fluorescent nuclear staining and detection with a fluorescence microscope equipped with a grid. A comparison of the numbers of migrating cells in successive 0.5 mm x 0.5 mm areas is shown in Fig 15A. As can be seen from the columns, VEGF-C-containing CM stimulated cell migration more than medium conditioned by the non-transfected or mock-transfected cells but less than medium from cells transfected with a VEGF expression vector. An

example of typical phase contrast and fluorescent microscopic fields of cultures stimulated with medium from mock-transfected or VEGF-C transfected cells is shown in Fig. 15B. Daily addition of 1 ng of FGF2 into the wells resulted in the migration of approximately twice the number of cells when compared to the stimulation by CM from VEGF-transfected cells.

EXAMPLE 16

VEGF-C Is Expressed In Multiple Tissues

Northern blots containing 2 micrograms of isolated poly(A)⁺ RNA from multiple human tissues (blot from Clontech) were probed with radioactively labelled insert of the 2.0 kb VEGF-C cDNA clone. Northern blotting and hybridization analysis showed that the 2.4 kb RNA and smaller amounts of a 2.0 kb mRNA are expressed in multiple human tissues, most prominently in the heart, placenta, muscle, ovary and small intestine (Fig. 16A). Very little VEGF-C RNA was seen in the brain, liver or thymus and peripheral blood leukocytes (pbl) appeared negative. A similar analysis of RNA from human fetal tissues (Fig. 16B) shows that VEGF-C is highly expressed in the kidney and lung and to a lesser degree in the liver, while essentially no expression is detected in the brain. Interestingly, VEGF expression correlates with VEGF-C expression in these tissues, whereas VEGF-B is highly expressed in all tissues analysed.

EXAMPLE 17

The VEGF-C Gene Localizes To Chromosome 4q34

A DNA panel of 24 interspecies somatic cell hybrids, which had retained one or two human chromosomes, was used for the chromosomal localization of the VEGF-C gene (Bios Laboratories, Inc., New Haven, CT). Primers were designed to amplify an about 250 bp fragment of the VEGF-C gene from somatic cell hybrid DNA. The primers and conditions for polymerase chain reaction (PCR) were 5'-TGAGTGATTGTAGCTGCTGTG-3' (forward) [SEQ ID NO:34] and 5'-TATTGCAGCAACCCCCACATCT-3' (reverse) [SEQ ID NO:35] for VEGF-C (94°C, 60s/62°C, 45s/72°C, 60s). The PCR products were evaluated by electrophoresis in 1% agarose gels and visualized by ethidium bromide staining in ultraviolet light. [α -³²P]-dCTP-labelled cDNA inserts of a plasmid representing the complete VEGF-C coding

domain was used as a probe in Southern blotting and hybridization analysis of the somatic cell hybrid DNAs as instructed by the supplier (Bios Laboratories).

The cell lines for fluorescence *in situ* hybridization (FISH) were obtained from the American Type Culture Collection (Rockville, MD).

- 5 Purified DNA from P1 clones 7660 and 7661 (VEGF-C) (Genome Systems, Inc., St. Louis, MO) were confirmed positive by Southern blotting of Eco RI-digested DNA followed by hybridization with the VEGF-C cDNA. The P1 clones were then labelled by nick translation either with biotin-11-dUTP, biotin-14-ATP (Sigma Chemical Co., St. Louis, MO) or digoxigenin 11-dUTP.
- 10 (Boehringer Mannheim GmbH, Mannheim, Germany) according to standard protocols. PHA-stimulated peripheral blood lymphocyte cultures were treated with 5-bromodeoxyuridine (BrdU) at an early replicating phase to induce G-banding. See Takahashi *et al.*, *Human Genet.*, 86:14-16 (1995); Lemieux *et al.*, *Cytogenet. Cell Genet.*, 59:311-12 (1992). The FISH procedure was
- 15 carried out in 50% formamide, 10% dextran sulphate in 2x SSC using well-known procedures. See, e.g., Rytkönnen *et al.*, *Cytogenet. Cell Genet.*, 68:61-63 (1995); Lichter *et al.*, *Proc. Natl. Acad. Sci. USA*, 85:9664-68 (1988). Repetitive sequences were suppressed with 50-fold excess of Cot-1 DNA (BRL, Gaithersburg, MD) compared with the labeled probe. Specific
- 20 hybridization signals were detected by incubating the hybridized slides in labelled antidigoxigenin antibodies, followed by counterstaining with 0.1mmol/L 4,6-diamino-2-phenylindole. Probe detection for two-color experiments was accomplished by incubating the slides in fluorescein isothiocyanate (FITC)-anti-digoxigenin antibodies (Sigma Chemical Co.) and
- 25 Texas red-avidin (Vector Laboratories, Burlingame, CA) or rhodamine-anti-digoxigenin and FITC-avidin.

- Multi-color digital image analysis was used for acquisition, display and quantification of hybridization signals of metaphase chromosomes. The system contains a PXL camera (Photometrics Inc., Tucson, AZ) attached
- 30 to a PowerMac 7100/Av workstation. IPLab software controls the camera operation, image acquisition and Ludl Filter wheel. At least 50 nuclei were scored. Overlapping nuclei and clusters of cells were ignored. A slide containing normal lymphocyte metaphase spreads and interphase nuclei was included in each experiment to control for the efficiency and specificity of the
- 35 hybridization.

In order to determine the chromosomal localization of the human VEGF-C gene, DNAs from human rodent somatic cell hybrids containing defined sets of human chromosomes were analysed by Southern blotting and hybridization with the VEGF-C cDNA probe. Among 24 DNA samples on the hybrid panel, representing different human chromosomes, human-specific signals were observed only in hybrids which contained human chromosome 4. The results were confirmed by PCR of somatic cell hybrid DNA using VEGF-C specific primers, where amplified bands were obtained only from DNAs containing human chromosome 4.

A genomic P1 plasmid for VEGF-C was isolated using specific primers and PCR and verified by Southern blotting and hybridization using a VEGF-B specific cDNA probe. The chromosomal localization of VEGF-C was further studied using metaphase FISH. Using the P1 probe for VEGF-C in FISH a specific hybridization to the 4q34 chromosomal band was detected in 40 out of 44 metaphases (Fig. 17). Double-fluorochrome hybridization using a cosmid probe specific for the aspartylglucosaminidase (AGA) gene showed that VEGF-C is located just proximal to the AGA gene previously mapped to the 4q34-35 chromosomal band.

Biotin labelled VEGF-C P1 and digoxigenin labeled AGA cosmid probes were hybridized simultaneously to metaphase chromosomes. This experiment demonstrated that the AGA gene is more telomerically located than the VEGF-C gene. The foregoing example demonstrates the utility of polynucleotides of the invention as chromosomal markers.

EXAMPLE 18

Effect of glucose concentration and hypoxia on VEGF, VEGF-B and VEGF-C mRNA levels in C6 glioblastoma cells

Confluent cultures of C6 cells (ATCC CCL 107) were grown on 10 cm diameter tissue culture plates containing 2.5 ml of DMEM and 5% fetal calf serum plus antibiotics. The cultures were exposed for 16 hours to normoxia in a normal cell culture incubator containing 5% CO₂ (Fig. 18: lanes marked -) or hypoxia (Fig. 18: lanes marked +) by closing the culture plates in an airtight glass chamber and burning a piece of wood inside until the flame was extinguished due to lack of oxygen. Polyadenylated RNA was

isolated (as in the other examples), and 8 micrograms of the RNA was electrophoresed and blot-hybridized with a mixture of the VEGF, VEGF-B and VEGF-C probes (see Fig. 12). The results show that hypoxia strongly induces VEGF-A mRNA expression (compare lanes - and +), both in low and high
5 glucose, but has no significant effect on the VEGF-B mRNA levels. The VEGF-C mRNA isolated from hypoxic cells runs slightly faster in gel electrophoresis and an extra band of faster mobility can be seen below the upper mRNA band. This observation suggests that hypoxia affects VEGF-C
10 RNA processing. One explanation for this observation is that VEGF-C mRNA splicing is altered, affecting the VEGF-C open reading frame and resulting in an alternative VEGF-C protein being produced by hypoxic cells. Such alternative forms of VEGF-C and VEGF-C-encoding polynucleotides are contemplated as an aspect of the invention.

Deposit of Biological Materials: Plasmid FLT4-L has been
15 deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Dr., Rockville MD 20952 (USA), pursuant to the provisions of the Budapest Treaty, and has been assigned a deposit date of 24 July 1995 and ATCC accession number 97231.

While the present invention has been described in terms of
20 specific embodiments, it is understood that variations and modifications will occur to those in the art. Accordingly, only such limitations as appear in the appended claims should be placed on the invention.



- 40 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Alitalo, Kari
Joukov, Vladimir

(ii) TITLE OF INVENTION: Receptor Ligand

(iii) NUMBER OF SEQUENCES: 35

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
(B) STREET: 6300 Sears Tower, 233 South Wacker Drive
(C) CITY: Chicago
(D) STATE: Illinois
(E) COUNTRY: United States of America
(F) ZIP: 60606-6402

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Gass, David A.
(B) REGISTRATION NUMBER: 38,153
(C) REFERENCE/DOCKET NUMBER: 28113/33072

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 312/474-6300
(B) TELEFAX: 312/474-0448
(C) TELEX: 25-3856

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TGTCCTCGCT GTCTTGCT

20

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 70 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ACATGCATGC CACCATGCAG CCGGCGCCG CGCTGTGCTT GCGACTGTGG CTCTGCTTGG

60

GACTCTGGA

70

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ACATGCATGC CCCGCCGGTC ATCC

24

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CGGAATTCCC CATGACCCCA AC

22

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCATCGATGG ATCCTACCTG AAGCCGCTTT CTT

33

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

ATTTAGGTGA CACTATA

17

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 34 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CCATCGATGG ATCCCGATGC TGCTTAGTAG CTTT

34

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 amino acids

- 42 -

(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Pro Met Thr Pro Thr Tyr Lys Gly Ser Val Asp Asn Gln Thr Asp
1 5 10 15
Ser Gly Met Val Leu Ala Ser Glu Glu Phe Glu Gln Ile Glu Ser Arg
20 25 30
His Arg Gln Glu Ser Gly Phe Arg
35 40

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CTGGAGTCGA CTGGCGGAC T

21

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 60 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGCGGATCCC TAGTGATGGT GATGGTGATG TCTACCTTCG ATCATGCTGC CCTTATCCTC

60

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CCCAAGCTTG GATCCAAGTG GCTACTCCAT GACC

34

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GTTCGCTGTG ATGTGCACCA

20

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Xaa Glu Glu Thr Ile Lys Phe Ala Ala Ala His Tyr Asn Thr Glu Ile
 1 5 10 15
 Leu Lys

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GCAGARGARA CNATHAA

17

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Glu Glu Thr Ile Lys
 1 5

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCAYTTNARD ATYTCTGT

18

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Xaa Glu Glu Thr Ile Lys Phe Ala Ala Ala His Tyr Arg Thr Glu Ile
 1 5 10 25

Leu Lys

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GCAGARGARA CNATHAA

17

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Glu Glu Thr Ile Lys
 1 5

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCATTNARD ATTTCGT

18

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Thr Glu Ile Leu Lys
1 5

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

ATTGCTGCA GCACACTACA AC

22

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TCNGTGTGT AGTGTGCTG

19

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Ala Ala His Tyr Asn Thr Glu
1 5

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

TAATACGACT CACTATAGGG

20

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GTGTAGTGT GCTGCAGCGA ATTT

24

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Lys Phe Ala Ala Ala His Tyr Asn
1 5

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

TCACTATAGG GAGACCCAAG C

21

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 219 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TCACTATAGG GAGACCCAAG CTGGTACCG AGCTGGATC CACTAGTAAC GGCCGCCAGT

60

GTGGTGGAA TCGACGAAC CATGACTGTA CTCTACCCAG AATATTGGAA AATGTACAAG

120

TGTCAGCTAA GGCAAGGAGG CTGGCAACAT AACAGAGAAC AGGCCAACCT CAACTCAAGG

180

ACAGAAGAGA CTATAAAATT CGCTGCAGCA CACTACAAC

219

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

ACAGAGAACA GGCCAACC

18

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

TCTAGCATT AGGTGACAC

19

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

AAGAGACTAT AAAATTGCT GCAC

25

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CCCTCTAGAT GCATGCTCGA

20

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GTGTAGTGT GCTGCAGCGA ATTT

24

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

TCACTATAGG GAGACCCAG C

21

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1140 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 37..1089

(ix) FEATURE:

(A) NAME/KEY: mat_peptide

(B) LOCATION: 133..1089

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

GAGCAGTTAC GGTCTGTGTC CAGTGTAGAT GAATCTC	ATG ACT GTA CTC TAC CCA	54
	Met Thr Val Leu Tyr Pro	
	-32 -30	
GAA TAT TGG AAA ATG TAC AAG TGT CAG CTA AGG AAA GGA GGC TGG CAA		102
Glu Tyr Trp Lys Met Tyr Lys Cys Gln Leu Arg Lys Gly Gly Trp Gln		
-25 -20 -15		
CAT AAC AGA GAA CAG GCC AAC CTC AAC TCA AGG ACA GAA GAG ACT ATA		150
His Asn Arg Glu Gln Ala Asn Leu Asn Ser Arg Thr Glu Glu Thr Ile		
-10 -5 1 5		
AAA TTT GCT GCA GCA CAT TAT AAT ACA GAG ATC TTG AAA AGT ATT GAT		198
Lys Phe Ala Ala Ala His Tyr Asn Thr Glu Ile Leu Lys Ser Ile Asp		
10 15 20		
AAT GAG TGG AGA AAG ACT CAA TGC ATG CCA CGG GAG GTG TGT ATA GAT		246
Asn Glu Trp Arg Lys Thr Gln Cys Met Pro Arg Glu Val Cys Ile Asp		
25 30 35		
GTG GCG AAG GAG TTT GGA GTC GCG ACA AAC ACC TTC TTT AAA CCT CCA		294
Val Gly Lys Glu Phe Gly Val Ala Thr Asn Thr Phe Phe Lys Pro Pro		
40 45 50		
TGT GTG TCC GTC TAC AGA TGT GGG GGT TGC TGC AAT AGT GAG GGG CTG		342
Cys Val Ser Val Tyr Arg Cys Gly Gly Cys Asn Ser Glu Gly Leu		
55 60 65 70		
CAG TGC ATG AAC ACC AGC ACG AGC TAC CTC AGC AAG ACG TTA TTT GAA		390
Gln Cys Met Asn Thr Ser Thr Ser Tyr Leu Ser Lys Thr Leu Phe Glu		
75 80 85		
ATT ACA GTG CCT CTC TCT CAA GGC CCC AAA CCA GTA ACA ATC AGT TTT		438
Ile Thr Val Pro Leu Ser Gln Gly Pro Lys Pro Val Thr Ile Ser Phe		
90 95 100		
GCC AAT CAC ACT TCC TGC CGA TGC ATG TCT AAA CTG GAT GTT TAC AGA		486
Ala Asn His Thr Ser Cys Arg Cys Met Ser Lys Leu Asp Val Tyr Arg		
105 110 115		
CAA GTT CAT TCC ATT ATT AGA CGT TCC CTG CCA GCA ACA CTA CCA CAG		534
Gln Val His Ser Ile Ile Arg Arg Ser Leu Pro Ala Thr Leu Pro Gln		
120 125 130		
TGT CAG GCA GCG AAC AAG ACC TGC CCC ACC AAT TAC ATG TGG AAT AAT		582
Cys Gln Ala Ala Asn Lys Thr Cys Pro Thr Asn Tyr Met Trp Asn Asn		
135 140 145 150		
CAC ATC TGC AGA TGC CTG GCT CAG GAA GAT TTT ATG TTT TCC TCG GAT		630
His Ile Cys Arg Cys Leu Ala Gln Glu Asp Phe Met Phe Ser Ser Asp		
155 160 165		
GCT GGA GAT GAC TCA ACA GAT GGA TTC CAT GAC ATC TGT GGA CCA AAC		678
Ala Gly Asp Asp Ser Thr Asp Gly Phe His Asp Ile Cys Gly Pro Asn		
170 175 180		
AAG GAG CTG GAT GAA GAG ACC TGT CAG TGT GTC TGC AGA GCG GCG CTT		726
Lys Glu Leu Asp Glu Glu Thr Cys Gln Cys Val Cys Arg Ala Gly Leu		
185 190 195		

CGG CCT GCC AGC TGT GGA CCC CAC AAA GAA CTA GAC AGA AAC TCA TGC Arg Pro Ala Ser Cys Gly Pro His Lys Glu Leu Asp Arg Asn Ser Cys 200 205 210	774
CAG TGT GTC TGT AAA AAC AAA CTC TTC CCC AGC CAA TGT GGG GCC AAC Gln Cys Val Cys Lys Asn Lys Leu Phe Pro Ser Gln Cys Gly Ala Asn 215 220 225 230	822
CGA GAA TTT GAT GAA AAC ACA TGC CAG TGT GTA TGT AAA AGA ACC TGC Arg Glu Phe Asp 235 Asn Thr Cys Gln Cys Val Cys Lys Arg Thr Cys 240 245	870
CCC AGA AAT CAA CCC CTA AAT CCT GGA AAA TGT GCC TGT GAA TGT ACA Pro Arg Asn 250 Pro Leu Asn Pro Gly Lys Cys Ala Cys Glu Cys Thr 255 260	918
GAA AGT CCA CAG AAA TGC TTG TTA AAA GGA AAG AAG TTC CAC CAC CAA Glu Ser Pro Gln Lys Cys Leu Leu Lys Gly Lys Lys Phe His His Gln 265 270 275	966
ACA TGC AGC TGT TAC AGA CGG CCA TGT ACG AAC CGC CAG AAG GCT TGT Thr Cys Ser Cys Tyr Arg Arg Pro Cys Thr Asn Arg Gln Lys Ala Cys 280 285 290	1014
GAG CCA GGA TTT TCA TAT AGT GAA GAA GTG TGT CGT TGT GTC CCT TCA Glu Pro Gly Phe Ser Tyr Ser Glu Glu Val Cys Arg Cys Val Pro Ser 295 300 305 310	1062
TAT TGG AAA AGA CCA CAA ATG AGC TAA GATTGACTG TTTTCCAGTT Tyr Trp Lys Arg Pro Gln Met Ser 315	1109
CATCGATTIT CTATTATGGA AAACITGTTT G	1140

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 350 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Met Thr Val Leu Tyr Pro Glu Tyr Trp Lys Met Tyr Lys Cys Gln Leu -32 -30 -25 -20
Arg Lys Gly Gly Trp Gln His Asn Arg Glu Gln Ala Asn Leu Asn Ser -15 -10 -5
Arg Thr Glu Glu Thr Ile Lys Phe Ala Ala Ala His Tyr Asn Thr Glu 1 5 10 15
Ile Leu Lys Ser Ile Asp Asn Glu Trp Arg Lys Thr Gln Cys Met Pro 20 25 30
Arg Glu Val Cys Ile Asp Val Gly Lys Glu Phe Gly Val Ala Thr Asn 35 40 45
Thr Phe Phe Lys Pro Pro Cys Val Ser Val Tyr Arg Cys Gly Gly Cys 50 55 60
Cys Asn Ser Glu Gly Leu Gln Cys Met Asn Thr Ser Thr Ser Tyr Leu 65 70 75 80
Ser Lys Thr Leu Phe Glu Ile Thr Val Pro Leu Ser Gln Gly Pro Lys 85 90 95
Pro Val Thr Ile Ser Phe Ala Asn His Thr Ser Cys Arg Cys Met Ser 100 105 110

Lys Leu Asp Val Tyr Arg Gln Val His Ser Ile Ile Arg Arg Ser Leu
 115 120 125
 Pro Ala Thr Leu Pro Gln Cys Gln Ala Ala Asn Lys Thr Cys Pro Thr
 130 135 140
 Asn Tyr Met Trp Asn Asn His Ile Cys Arg Cys Leu Ala Gln Glu Asp
 145 150 155 160
 Phe Met Phe Ser Ser Asp Ala Gly Asp Asp Ser Thr Asp Gly Phe His
 165 170 175
 Asp Ile Cys Gly Pro Asn Lys Glu Leu Asp Glu Glu Thr Cys Gln Cys
 180 185 190
 Val Cys Arg Ala Gly Leu Arg Pro Ala Ser Cys Gly Pro His Lys Glu
 195 200 205
 Leu Asp Arg Asn Ser Cys Gln Cys Val Cys Lys Asn Lys Leu Phe Pro
 210 215 220
 Ser Gln Cys Gly Ala Asn Arg Glu Phe Asp Glu Asn Thr Cys Gln Cys
 225 230 235 240
 Val Cys Lys Arg Thr Cys Pro Arg Asn Gln Pro Leu Asn Pro Gly Lys
 245 250 255
 Cys Ala Cys Glu Cys Thr Glu Ser Pro Gln Lys Cys Leu Leu Lys Gly
 260 265 270
 Lys Lys Phe His His Gln Thr Cys Ser Cys Tyr Arg Arg Pro Cys Thr
 275 280 285
 Asn Arg Gln Lys Ala Cys Glu Pro Gly Phe Ser Tyr Ser Glu Glu Val
 290 295 300
 Cys Arg Cys Val Pro Ser Tyr Trp Lys Arg Pro Gln Met Ser
 305 310 315

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

TGAGTGATTGTAGCTGCTG

22

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

TATTGCAGCAACCCCACTCT

22

CLAIMS

1. A purified and isolated polypeptide which specifically binds to the Flt4 receptor tyrosine kinase.
2. A purified and isolated polypeptide having the amino acid sequence shown in SEQ ID NO: 33.
3. A purified and isolated nucleic acid encoding the peptide according to claim 2.
4. The nucleic acid according to claim 3 having the sequence shown in SEQ ID NO: 32.
5. A vector comprising the nucleic acid according to claim 4.
6. The vector according to claim 5, wherein said vector is plasmid pFLT4-L, deposited as ATCC accession No. 97231.
7. A host cell comprising the vector according to claim 6.
8. A fragment of the purified and isolated polypeptide according to claim 2, said fragment being capable of specifically binding to an Flt4 receptor tyrosine kinase.
9. The fragment according to claim 8 having an apparent molecular weight of 23 kD under reducing conditions.
10. The fragment according to claim 8 comprising approximately amino acids 1-120 of SEQ ID NO: 33.
11. A purified and isolated nucleic acid encoding the fragment of claim 10.

12. The fragment according to claim 8 comprising approximately amino acids 1-180 shown in SEQ ID NO: 33.

13. A purified and isolated nucleic acid encoding the fragment of claim 12.

14. An antibody which is specifically reactive with the Flt4 ligand.

15. An antibody of claim 14 which is a monoclonal antibody.

16. A pharmaceutical composition comprising a polypeptide according to claim 2 in a pharmaceutically-acceptable diluent, adjuvant, or carrier.



- 52 -

ABSTRACT

Provided are ligands for the receptor tyrosine kinase, Flt4. Also provided are cDNAs and vectors encoding the ligand, pharmaceutical compositions and diagnostic reagents.

#2 1/2

Atty. Docket No: 28113/33072

DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled "RECEPTOR LIGAND," the specification of which was filed on January 12, 1996, as Application Serial No. 08/585,895. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Priority Claimed
☐ Yes ☐ No

(Application Serial Number) (Country) (Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

(Application Serial Number) (Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

08/510,133 01 August 1995 Pending
(Application Serial Number) (Day/Month/Year Filed) (Status-Patented, Pending or Abandoned)

(Application Serial Number) (Day/Month/Year Filed) (Status-Patented, Pending or Abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: I hereby appoint as my attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Alvin D. Shulman (19,412)
Donald J. Brox (19,490)
Owen J. Murray (22,111)
Allen H. Gerstein (23,218)
Nate F. Scarpelli (23,120)
Edward M. O'Toole (22,477)
Michael F. Borun (25,447)

Trevor B. Joike (25,542)
Timothy J. Vezou (26,348)
Carl E. Moore, Jr. (26,487)
Richard H. Anderson (26,526)
Patrick D. Ertel (26,877)
James P. Zeller (28,491)
William E. McCracken (30,195)

Richard A. Schoultz (30,890)
Anthony Nimmo (30,920)
Christine A. Dudzik (31,245)
Kevin D. Hogg (31,839)
Jeffrey S. Sharp (31,879)
Donald J. Pochopien (32,167)
Martin J. Hirsch (32,237)

James J. Napoli (32,361)
Richard M. Le Barge (32,254)
Jeffrey W. Smith (33,455)
Douglas C. Hochstetler (33,710)
Cynthia L. Schaller (34,245)
Robert M. Gerstein (34,824)
David A. Gass (38,153)

Send correspondence to: David A. Gass

FIRM NAME	PHONE NO.	STREET	CITY & STATE	ZIP CODE
Marshall, O'Toole, Gerstein, Murray & Borun	312-474-6300	6300 Sears Tower 233 South Wacker Drive	Chicago, Illinois	60606-6402
Kari Ahtala		Citizenship Finland		
Residence Address - Street		Post Office Address - Street		
Nyyrikantie 4A		Same		
City (Zip)		City (Zip)		
02100 Espoo		Same		
State or Country		State or Country		
FINLAND		Same		
Date		Signature		
March 14, 1996		Norm Ohtala		

See second page for additional inventor

See reverse for relevant rules & statutes

2-80

Second Joint Investor, if any Vladimir Joukov	Citizenship Finland <i>Russia</i>
Residence Address - Street Topelintuokatu 32G8	Post Office Address - Street Same
City (Zip) 00290 Helsinki <i>ELX</i>	City (Zip) Same
State or Country FINLAND	State or Country Same
Date March 14 1996	Signature V. Joukov

2-50

Second Joint Investor, if any Vladimir Jonkov	Citizenship Finland Russia
Residence Address - Street Topefiruksenkata 32G8	Post Office Address - Street Same
City (Zip) 00290 Helsinki FIX	City (Zip) Same
State or Country FINLAND	State or Country Same
Date March 14 1996	Signature V. Jonkov




FIGURE 1

00 585895





FIGURE 2

Figure 3



585595



FIGURE 4

585895





FIGURE 5


08 585895

FIGURE 6



585895



FIGURE 7



00 585895

00 585895

FIGURE 7



08 585895

FIGURE 8






FIG. 9A

98 585895



08 585895

MetThrValLeuTyrProGluTyr
 CACCACTTACCGTCTCTCTCCACTCTACATCACTCATCTACTCTACCTACCCAGATAT
 10 30 50
 TrpLysMetTyrLysCysGlnLeuArgLysGlyGlyTrpGlnHisAsnArgGluGlnAla
 TCGAAATGTACAACTGTCTACCTAGGAAAGGAGCGCTGCAACATAACACAGAACTGCCC
 70 90 110
 AsnLeuAsnSerArgThrGluGluThrIleLysPheAlaAlaAlaHisTyrAsnThrGlu
 AACCTCTACTCAACGACAGACAGACATATAAATTTCTGTCACCATATATATACACAC
 130 150 170
 IleLeuLysSerIleAspIleGluTrpArgLysThrGlnCysMetProArgGluValCys
 ATCTTGAAGTATTGATAATGAGTGGACAAAGACTCAATGCAATCCACCGAGGTCTGT
 190 210 230
 IleAspValGlyLysGluPheGlyValAlaThrAsnThrPhePheLysProProCysVal
 ATAGATCTCCCAAGCACTTTGCACTGCGGACAAACACCTTCTTAAACCTCCATCTGT
 250 270 290
 SerValTyrArgCysGlyGlyCysCysAsnSerGluGlyLeuGlnCysMetAsnThrSer
 TCCCTCTACAGATCTGCGGCTTCTGCAATAGTGAAGGCTGCACTGCAATCAACACACAC
 310 330 350
 ThrSerTyrLeuSerLysThrLeuPheGluIleThrValProLeuSerGlnGlyProLys
 ACCAGCTACCTCAGCAGACCTTATTGAAATGACCTGCTCTCTCAAGCCGCAAA
 370 390 410
 ProValThrIleSerPheAlaAsnHisThrSerCysArgCysMetSerLysLeuAspVal
 CCAGTACAAATCACTTTTCCCAATCAGACTTCTGCGGATGCACTCTCAAACTGATGTT
 430 450 470
 TyrArgGlnValHisSerIleIleArgArgSerLeuProAlaThrLeuProGlnCysGln
 TACAGACAGTTCACTTCCATATAGACCTTCCCTGCGGACAACTACCTACAGTGTGAC
 490 510 530
 AlaAlaAsnLysThrCysProThrAsnTyrMetTrpAsnAsnHisIleCysArgCysLeu
 CCAGCGACAAACACCTGCCCCACCAATGATGCTGCAATATCACTCTGACAGTCCCTG
 550 570 590
 AlaGlnGluAspPheMetPheSerSerAspAlaGlyAspAspSerThrAspGlyPheHis
 CCTCAGCAGATTTTATGTTTCTCTGCACTGCTGCACTCAACACATGCAATTCAT
 610 630 650
 AspIleCysGlyProAsnLysGluLeuAspGluGluThrCysGlnCysValCysArgAla
 CACATCTCTGACCAACACAGGAGCTGCAATGACAGACCTGTCTACTGTCTCTGACAGCG
 670 690 710
 GlyLeuArgProAlaSerCysGlyProHisLysGluLeuAspArgAsnSerCysGlnCys
 GCGCTTGGGCTGCGAGCTGTGACCCCAACAAAGAACTAGACAGAACTCATGCGAGTGT
 730 750 770
 ValCysLysAsnLysLeuPheProSerGlnCysGlyAlaAsnArgGluPheAspGluAsn
 CTCTGTAAACAAACTCTTCCCAACCAATGTGGGCAACCGAGATTTCAATCAAAAC
 790 810 830
 ThrCysGlnCysValCysLysArgThrCysProArgAsnGlnProLeuAsnProGlyLys
 ACATGCGAGTGTGATGTAAAGAACTTCCCAAGAAATCAACCCCTAAATCTCTGAAAA
 850 870 890
 CysAlaCysGluCysThrGluSerProGlnLysCysLeuLeuLysGlyLysLysPheHis
 TGTGCTGTGAAATGACAGAAAGTCCACAGAAATGCTGTGTAAGAAAGAGTTCCAC
 910 930 950
 HisGlnThrCysSerCysTyrArgArgProCysThrAsnArgGlnLysAlaCysGluPro
 CACCAACATCCAGCTGTTACAGACCGGCTGTACGAACCCGACAGCGCTTGTGAACCA
 970 990 1010
 GlyPheSerTyrSerGluGlnValCysArgCysValProSerTyrTrpLysArgProGln
 GCAATTTCTATAGTCAAGAACTCTCTGCTTCTGCTGCTTCAATGGAAGACACCAA
 1030 1050 1070
 MetSerEnd
 ATGAGCTAAGATTGACTGTTTTCAGTTTCATGATTTCTATTATCCAAAAGTCTGTTG
 1090 1110 1130

FIG. 9B

585895

1	5c
PDGF-A	.MRTWACILL LCCGYLAHAL AZEAEIPREL IERLARSQIH SIRDLOQLLE
PDGF-B	.MNRGWA.LFL SLCCYLRLVS AEGDPIPEEL YEMLSOHSIR SFDDLQRLLE
PIGF-1MPVM RLFFC..FLQ LLAGLAL...
PIGF-2MPVM RLFFC..FLQ LLAGLAL...
VEGF121M NFLLS..WVH WSLALLLYLH
VEGF165M NFLLS..WVH WSLALLLYLH
VEGF189M NFLLS..WVH WSLALLLYLH
VEGF206M NFLLS..WVH WSLALLLYLH
Flt4-LM TVLYPEYWKH YKCQLRKGGW
51	10c
PDGF-A	.IDSVGAEDAL ETSLEAHGSH AINHVPKXRP VPIRRKRSI.EEAIP
PDGF-B	.GDP.GEEDCA ELDLNMTRSH SCGELES... .LARGRRSLG SLTIAEPAMI
PIGF-1	.PAVPPQGW... .ALSAG NGSSEVEVVP FQE.VWGR..
PIGF-2	.PAVPPQGW... .ALSAG NGSSEVEVVP FQE.VWGR..
VEGF121	.HAKWSQAA... .PMAEG GGQNHHEVVK FMD.VYQR..
VEGF165	.HAKWSQAA... .PMAEG GGQNHHEVVK FMD.VYQR..
VEGF189	.HAKWSQAA... .PMAEG GGQNHHEVVK FMD.VYQR..
VEGF206	.HAKWSQAA... .PMAEG GGQNHHEVVK FMD.VYQR..
Flt4-L	.QHNREQANLN SRTEETIKFA AAHYNTIILX SIDNEWK..
101	15c
PDGF-A	.AVCKTRITVY EIPRSQVDPT SANFLIWPPC VEVKRCGCC NTSSVKCQPS
PDGF-B	.AECRTITEVF EISRLIDRT NANFLVWPPC VEVQRCGCC NNRNVCQRP
PIGF-1	.SYCRALERLV DVVSEYPS.. EVEHMFSPSC VSLLRCTGCC GDENLHCVPV
PIGF-2	.SYCRALERLV DVVSEYPS.. EVEHMFSPSC VSLLRCTGCC GDENLHCVPV
VEGF121	.SYCHPIETLV DIFQEYPD.. EIEYIFKPSC VPLMRCGCC NDEGLECVPT
VEGF165	.SYCHPIETLV DIFQEYPD.. EIEYIFKPSC VPLMRCGCC NDEGLECVPT
VEGF189	.SYCHPIETLV DIFQEYPD.. EIEYIFKPSC VPLMRCGCC NDEGLECVPT
VEGF206	.SYCHPIETLV DIFQEYPD.. EIEYIFKPSC VPLMRCGCC NDEGLECVPT
Flt4-L	.TQMPREVCV DVGKEFGV.. ATNTFFKPPC VSVYRCGCC NSEGLQCMNT
151	20c
PDGF-A	.RVHRSVKVA KVEYVRKKPK LKEVQVRLEE HLEACAT... ..SN
PDGF-B	.QVQLRPVQVR KIEIVRKCPV FKATVILEL HLACKCETVA AARPVTRSPG
PIGF-1	.ETANVTMQLL KIRSG..DRP .SYVELTFSQ HVRCECRPLR EKMKPER...
PIGF-2	.ETANVTMQLL KIRSG..DRP .SYVELTFSQ HVRCECRPLR EKMKPERRR.
VEGF121	.EESNITMQIM RIKPH..CQQ .HIGEMSFLQ HNKCECRPKK DRARQEKCD.
VEGF165	.EESNITMQIM RIKPH..CQQ .HIGEMSFLQ HNKCECRPKK DRARQEN...
VEGF189	.EESNITMQIM RIKPH..CQQ .HIGEMSFLQ HNKCECRPKK DRARQEKKS.
VEGF206	.EESNITMQIM RIKPH..CQQ .HIGEMSFLQ HNKCECRPKK DRARQEKKS.
Flt4-L	.STSYLSKTLF EITVPLSQGP .KPVITISFAN HTSCRCMSKL DVYRQVHSII
201	25c
PDGF-A	.LNPDRHEEET DVR.....
PDGF-B	.GSQEQRATP QTRVTIATVR VRRPPKGGHR KFKHTHDKIA LKETLGA...
PIGF-1CGDAVPR R.....
PIGF-2PKGRGK RRREKQRPD CHLCGDAVPR R.....
VEGF121KPRR.....
VEGF165P.....
VEGF189VRGCKK GQRRKRKSR YKSWSV.....
VEGF206VRGCKK GQRRKRKSR YKSWSVYVGA RCC.....L MPWSLPGPH
Flt4-L	.RRSLPATLPQ CQAANKTCPT NYMWNHICR CLAQEDFMFS SDAGDDSTDC

FIG. 10

585895

	251			300
PDGF-A
PDGF-B
PIGF-1
PIGF-2
VEGF121
VEGF165	CGPCSEERRKH	LFVQDPQTCK	CSCXWTD SRC	KARQLELNER TCRCDKPRR.
VEGF189	CGPCSEERRKH	LFVQDPQTCK	CSCXWTD SRC	KARQLELNER TCRCDKPRR.
VEGF206	CGPCSEERRKH	LFVQDPQTCK	CSCXWTD SRC	KARQLELNER TCRCDKPRR.
Flt4-L	FHDICGPNKE	LDEETCQCVC	RAGLRPASCG	PHKELDRNSC QCVCKNKLFP
	301			350
PDGF-A
PDGF-B
PIGF-1
PIGF-2
VEGF121
VEGF165
VEGF189
VEGF206
Flt4-L	SQCGANREFD	ENTCQCVCXR	TCPRNQPLNP	GKACECTES PQKCLLKGRK
	351			394
PDGF-A
PDGF-B
PIGF-1
PIGF-2
VEGF121
VEGF165
VEGF189
VEGF206
Flt4-L	FHHQTCSCYR	RPCTNRQKAC	EPGFSYSEEV	CRCVPSYWKR PQMS

FIG. 10

00 585895




FIGURE 11

88 585895




FIGURE 12

585895





FIG. 13A


08 585895

FIG. 13B -




585895

FIG. 14A




585895

FIG. 14B



585895

FIG. 15A



585895

FIG. 15A




FIG. 15B





FIG. 16A



585895




FIG. 16B

585895

FIG. 17

Chr 4



1 VEGF-C,q34

585895




FIG. 18